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Abstract 
 
The human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) pandemic continues to be a major global cause of illness, disability and 
death. Men and women engaged in unprotect receptive anal intercourse are at high 
risk of acquiring HIV from infected partners. The implementation of additional 
preventive strategies is urgent and rectal microbicides may be useful tools in 
reducing the sexual transmission of HIV. The design and formulation of advanced 
microbicides, including those based on nanotechnology approaches, may help 
bypassing limitations of more conventional products currently under evaluation, 
namely regarding the poor ability to provide and sustain protective levels of 
microbicide drug candidates at the colorectum. Therefore, the main aim of this work 
was to develop polymeric nanoparticles (NPs) as delivery systems of antiretroviral 
(ARV) molecules in order to be used for the development of rectal microbicides 
intended to prevent sexual HIV transmission. 
Poly (lactic-co-glycolic acid) (PLGA)-based NPs were produced by 
nanoprecipitation and their surface modified or not with poloxamer 407, a triblock 
copolymer comprising polyethylene glycol (PEG) and propylene glycol (PPG) chains. 
Adsorption of poloxamer 407 at the surface of NPs was intended to provide a dense 
PEG corona that was able to confer mucus diffusive properties to otherwise 
mucoadhesive PLGA NPs. Both PLGA NPs and modified counterparts (PEG-PLGA 
NPs) featured average hydrodynamic diameter around 200-220 nm and narrow size 
distribution as determined by dynamic light scattering. Alongside an increase in zeta 
potential (ZP) to near neutral values upon modification, the presence of PEG chains 
at the surface of PEG-PLGA NPs was confirmed by proton nuclear magnetic 
resonance, energy dispersive spectroscopy and contact angle measurements. The 
distribution and retention patterns of fluorescently labelled PLGA NPs and PEG-
PLGA NPs were further assessed in a mouse model after rectal administration by 
qualitative in vivo imaging and a quantitative method based on the fluorescence 
signal recovery from colorectal lavages and tissue homogenates. Both types of NPs 
were mainly distributed throughout the last two thirds of the colon of mice even if 
rapid depletion was observed. Notably, PEG-PLGA NPs showed significantly 
improved retention in colonic tissues and fluids at 15 min and 2 h after administration, 
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respectively. Also, microscopic analysis of transversal sections of the colorectum 
showed that PEG-PLGA NPs were able to widely distribute throughout the epithelial 
surface (including at tissue folds), while PLGA NPs were mainly immobilized at the 
central part of the gut lumen. 
In order to understand the potential of developed NPs as rectal microbicide 
drug carriers, the ARV drug efavirenz (EFV) was associated to both PLGA NPs and 
PEG-PLGA NPs by adapting the nanoprecipitation procedure. The incorporation of 
EFV did not change substantially the colloidal properties of plain PLGA NPs and 
PEG-PLGA NPs. High values of association efficiency (around 85%) and drug 
loading (approximately 4%) were determined for both types of EFV-loaded NPs. 
Particles were also shown able to release EFV under sink conditions, with 
approximately 60% of the total drug content being release within the first hour. 
Association to NPs reduced the intrinsic cytotoxicity of EFV while maintaining its ARV 
activity, as assessed in a TZM-bl cell-based assay. Potential safety of both types of 
EFV-loaded NPs was also confirmed in cell-based assays using relevant epithelial 
cell lines of colorectal origin. Drug-loaded NPs were further shown to be readily taken 
up by colorectal epithelial cell lines and to mildly reduce the intestinal permeability as 
determined in cell monolayer models. 
Finally, the local and systemic pharmacokinetic profiles of EFV-loaded PLGA 
NPs and EFV-loaded PEG-PLGA NPs were assessed between 15 min and 12 h after 
rectal administration to mice. The levels of EFV in the colorectum were generally 
increased when EFV was incorporated into NPs as compared to the free drug. 
Importantly, PEG-PLGA NPs provided higher local levels of EFV than PLGA NPs. 
For example, bioavailability values for EFV-loaded PEG-PLGA NPs in tissues of the 
middle section of the colon were around 29- and 6-fold higher than those obtained for 
free EFV and PLGA NPs, respectively. Systemic exposure to EFV was low in all 
cases. Also, both types of drug-loaded NPs were found safe upon 14 days of daily 
rectal administration to mice. 
Overall, PLGA-based NPs were shown to be promising ARV drug carriers with 
potential application in the development of rectal anti-HIV microbicide products. 
 
Keywords: efavirenz, mucus-penetrating particles, nanomedicine, poly(lactic-co-
glycolic acid), pre-exposure prophylaxis, rectal administration. 
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Resumo1           
  
A pandemia causada pelo vírus da imunodeficiência humana/síndrome da 
imunodeficiência adquirida  (VIH/SIDA) continua a ser globalmente uma causa 
significativa de doença, incapacidade e morte. Homens e mulheres que praticam 
sexo anal receptivo desprotegido apresentam elevado risco de adquirir VIH de 
parceiros infectados. A implementação de estratégias de prevenção adicionais é 
urgente e os microbicidas rectais podem constituir instrumentos úteis na redução da 
transmissão sexual do VIH. O design e formulação de microbicidas avançados, 
incluindo aqueles baseados em nano-tecnologia, podem ajudar a ultrapassar as 
limitações dos produtos mais convencionais actualmente em avaliação, 
nomeadamente no que diz respeito à sua limitada capacidade de providenciar e 
manter níveis protectores de fármacos candidatos a microbicidas a nível colo-rectal. 
Assim, o objectivo principal deste trabalho consistiu em desenvolver nano-partículas 
(NPs) poliméricas como plataformas para a entrega de moléculas anti-retrovirais que 
possam ser utilizadas no desenvolvimento de microbicidas rectais, com o objectivo 
de prevenir a transmissão sexual do VIH.   
NPs de ácido poli (láctico co-glicólico) (PLGA) foram produzidas por 
nanoprecipitação e a sua superfície foi modificada ou não com poloxamer 407, um 
co-polímero em tri-bloco constituído por cadeias de polietileno-glicol (PEG) e 
polipropileno-glicol (PPG). A adsorção do poloxamer 407 à superfície teve como 
objectivo proporcionar uma densa cobertura de PEG, capaz de conferir propriedades 
muco-difusivas às NPs de PLGA muco-adesivas. As NPs de PLGA e homólogas 
modificadas (PEG-PLGA NPs) apresentaram um diâmetro hidrodinâmico médio de 
cerca de 200-220nm e limitada distribuição de tamanho, como determinado por 
espalhamento dinâmico de luz. Juntamente com o aumento dos valores de potencial 
zeta para valores próximos da neutralidade, a presença das cadeias de PEG à 
superfície das NPs de PEG-PLGA foi confirmada por ressonância magnética nuclear 
de protões, espectroscopia de energia dispersiva e medições de ângulo de contacto. 
Os padrões de distribuição e retenção das NPs de PLGA e PEG-PLGA marcadas 
com uma sonda fluorescente foram estudados num modelo de ratinho após 
administração rectal, usando um modelo qualitativo de in vivo imaging  e um método 
                                                
1 Por vontade da autora, este texto não segue as regras do Acordo Ortográfico. 
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quantitativo baseado no sinal de fluorescência obtido a partir dos fluídos rectais e 
homogeneizados de tecidos. Ambos os tipos de NPs distribuíram ao longo dos 
últimos dois terços do cólon de ratinho, apesar da rápida depleção observada. 
Notavelmente, as NPs de PEG-PLGA apresentaram uma maior retenção nos tecidos 
e fluídos do cólon aos 15 min e 2 h após administração, respectivamente. Além 
disso, a análise microscópica de secções transversais do cólon/recto evidenciou que 
as NPs de PEG-PLGA distribuíram-se amplamente ao longo da superfície epitelial 
(incluindo ao nível das pregas de tecido), enquanto as NPs de PLGA ficaram 
maioritariamente imobilizadas na zona central do lúmen intestinal.  
De modo a perceber o potencial das NPs desenvolvidas como microbicidas 
rectais para entrega de fármacos, o fármaco anti-retroviral (ARV) efavirenz (EFV) foi 
associado às NPs de PLGA e PEG-PLGA, adaptando o procedimento de 
nanoprecipitação. A incorporação do fármaco não modificou substancialmente as 
propriedades coloidais exibidas pelas NPs de PLGA e PEG-PLGA antes da 
incorporação. Foram obtidos elevados valores de eficiência de associação (cerca de 
85%) e capacidade de carga (aproximadamente 4%) para ambos os tipos de NPs 
carregadas com EFV. As partículas também foram capazes de libertar o EFV em 
condições sink, sendo libertado cerca de 60% do conteúdo total de fármaco ao longo 
da primeira hora. A associação às NPs reduziu a cito-toxicidade intrínseca do EFV, 
mantendo simultaneamente a sua actividade ARV, como confirmado em ensaios 
baseados em células TZM-bl. O perfil de segurança de ambos os tipos de NPs 
carregadas com EFV foi também confirmado em ensaios celulares usando linhas 
celulares epiteliais de origem colo-rectal. Mais adiante, as NPs carregadas com 
fármaco foram rapidamente captadas por células epiteliais colo-rectais e mostraram-
se capazes de reduzir ligeiramente a permeabilidade intestinal, como estudado em 
modelos celulares em mono-camada.  
Finalmente, o perfil farmacocinético das NPs de PLGA e PEG-PLGA 
carregadas com EFV foi estudado entre 15 min e 12 h após a administração rectal a 
ratinho. Os níveis de EFV no cólon/recto foram geralmente mais elevados quando o 
fármaco estava incorporado nas NPs em comparação com o fármaco livre. De notar 
que as NPs de PEG-PLGA proporcionaram níveis locais mais elevados de EFV do 
que as NPs de PLGA. Por exemplo, os valores de biodisponibilidade obtidos para as 
NPs de PEG-PLGA nos tecidos da secção do cólon médio foram cerca de 29 e 6 
vezes mais elevados do que os obtidos para o fármaco livre e NPs de PLGA, 
 xvii 
 
respectivamente. A exposição sistémica ao EFV foi baixa em todos os casos. Além 
disso, a administração rectal diária durante 14 dias de ambos os tipos de NPs 
carregadas com fármaco mostrou-se segura. 
Globalmente, as NPs de PEG-PLGA mostraram-se promissoras como 
carregadoras de fármacos ARV e apresentam potencial para aplicação no 
desenvolvimento de produtos microbicidas rectais anti-VIH. 
  
Palavras-chave: ácido poli (láctico-co-glicólico), administração rectal, efavirenz, 
nano-medicina, partículas penetradoras de muco, profilaxia pré-exposição.  
            
            
            
  
 
 
 
     
          
 
 
 
     
          
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
     
 
     
          
                                         
                Segue o teu destino, 
Rega as tuas plantas, 
Ama as tuas rosas. 
O resto é a sombra 
De árvores alheias. 
 
 
A realidade 
Sempre é mais ou menos 
Do que nós queremos. 
Só nós somos sempre 
                Iguais a nós-próprios. 
 
         (…) 
    
 Ricardo Reis 
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1.1. Overview  
   
 The human immunodeficiency virus (HIV) infection remains a major global 
public health issue. Despite all efforts focused on treatment and prevention, around 
36.9 million people were living with HIV/acquired immunodeficiency syndrome (AIDS) 
worldwide by 2017, while 1.8 million new infections were estimated to have occurred 
in that year alone (1). During the same period, HIV was related to roughly 1 million 
deaths. Sexual transmission remains by far the predominant mode of HIV 
transmission (2, 3). Unprotect receptive anal intercourse (URAI), both associated to 
heterosexual and male homosexual intercourse, is an important route for acquiring 
the infection and is believed to be assuming an increasing role in the pandemic (4). 
Importantly, the estimated per-contact probability of HIV transmission by URAI has 
been estimated to be around 1.4%, around 18-fold higher than the risk of acquiring 
the infection through unprotect vaginal intercourse (5, 6). URAI is frequently linked to 
men who have sex with men (MSM). However, URAI seems to be a common practice 
between heterosexual couples, although the prevalence has likely been 
underestimated (7, 8). A review study conducted by McBride & Fortenberry estimates 
that around 30% of heterosexual women had anal sex, at least one time (7). Several 
preventive measures of rectal HIV transmission are currently available, with particular 
focus on condom use and, more recently, oral pre-exposure prophylaxis (PrEP) with 
antiretroviral (ARV) drugs. Despite none being considered fully protective, current 
thinking in the field points towards the combination of different partially effective 
measures as the best approach for tackling HIV numbers (9). 
In this context, rectal microbicides (topical PrEP) have been gaining substantial 
support as potential tools for the prevention of sexual HIV transmission. These can 
be defined as products containing anti-HIV compounds that are intended to be 
placed in the rectum in order to avoid early transmission events at the mucosal level 
upon sexual intercourse (10). Despite relevant progress in the field, several problems 
related with the formulation of products developed so far are hindering the 
development of an effective, safe and acceptable rectal microbicide (11). The 
suboptimal performance of conventional rectal dosage forms in which microbicide 
products are based on dictated the increased exploration of novel drug delivery 
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systems as platforms for the delivery of anti-HIV molecules. Substantial work from 
our group at i3S/INEB and others on vaginal microbicides (reviewed in (12) ) support 
that the use of nanotechnology-based systems may also be advantageous for the 
development of rectal microbicides. For example, nanocarriers hold the potential to 
improve colorectal drug distribution and retention, penetrate mucosal tissues and 
enhance the interactions with HIV target cells, leading to overall favorable 
pharmacokinetics (PK) that may allow reducing transmission. However, very little 
work has been undertaken in order to effectively assess these possibilities (11, 13). 
One additional and important issue has to deal with the optimal properties of 
nanosystems for rectal delivery. In particular, the paradigm that mucoadhesive 
particles may be beneficial for mucosal drug delivery has been disputed, with multiple 
reports advocating that mucus diffusive nanosystems (also referred to as mucus 
penetrating) can outperform these last in terms of local distribution and even 
retention (14-16). Understanding how specific engineering of the mucoadhesive 
properties of nanocarriers intended for rectal microbicide development affects 
performance upon administration seems of paramount relevance.   
 Therefore, the present work arises from the interest in further exploring the 
potential of nanotechnology-based rectal microbicides and is based on the 
hypothesis that specifically engineered nanocarriers may contribute to the enhanced 
performance of candidate microbicide drugs, namely regarding the achievement of 
favorable PK profiles. 
 
1.2. Aim and specific objectives 
 
The main aim of this work is to develop nanotechnology-based carriers as 
delivery platforms for ARV drugs intended to be used as rectal microbicides in the 
prevention of sexual HIV transmission. In order to accomplish this aim, several 
specific objectives are proposed, namely: 
 To develop and characterize relevant physicochemical and technological 
properties of polymeric NPs based on poly (lactic-co-glycolic acid) (PLGA), 
while considering or not the modification of their surface with a dense 
polyethylene glycol (PEG) corona in order to yield mucus diffusive or 
mucoadhesive properties, respectively; 
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 To test the influence of surface modification with PEG on the colorectal 
distribution and retention of PLGA NPs following rectal administration to an 
animal model; 
 To associate the ARV drug efavirenz (EFV) to PLGA NPs, either modified or 
not with PEG, and to characterize their relevant physicochemical and 
technological properties;  
 To ascertain on the biological properties of developed NPs, namely regarding 
cytotoxicity, cellular uptake, ARV activity and epithelial permeability by using 
relevant in vitro cell-based models; 
 To evaluate the PK of EFV after rectal administration of drug-loaded NPs, as 
well as their safety, by using an animal model. 
 
This Thesis is organized in five chapters. In Chapter 1, a general framework of 
the theme is given as well as the motivations and aim of the study. Also, the 
objectives to achieve the proposed aim are specified. In Chapter 2, a thorough 
review of the literature is provided concerning the overall development of rectal 
microbicides, including detailed background on the topic of nanotechnology-based 
approaches. Chapter 3 details on the experimental work regarding the development 
and characterization of PLGA-based NPs, without or with surface modification by 
PEG, in order to obtain either mucoadhesive (PLGA NPs) or mucus diffusive (PEG-
PLGA NPs) systems. Also, the role of developed NPs in the distribution and retention 
in the colorectum of mice after rectal administration is discussed. Chapter 4 
describes efforts undertaken in order to develop EFV-loaded PLGA NPs and EFV-
loaded PEG-PLGA NPs and characterize their physicochemical and technological 
properties. Studies on the interactions between nanosystems and cells are also 
detailed, namely regarding toxicity, ARV activity, cell uptake, and drug epithelial 
permeability and retention. Additionally, this chapter presents and discusses data 
regarding the ability of developed drug-loaded NPs to modulate the PK of EFV after 
rectal administration to a mouse model. Data concerning the safety of NPs after 14 
days of once daily rectal administration is further described. Finally, Chapter 5 
includes the overall conclusions of the work as discusses several possibilities 
regarding future studies. 
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2.1. The rectum: basic aspects  
 
2.1.1. Biology of the rectum  
 
The rectum comprises the distal 15-20 cm of the gastrointestinal tract (GIT), 
with a total surface area of 200-400 cm2 (1, 2). It extends from the sigmoid colon to 
the pectinate line, where the anal canal begins (Figure 2.1). It can be divided into 
three distinct parts: the upper, middle and lower rectum (3). The mucosa of the 
rectum is composed of simple columnar epithelium forming crypts of Lieberkühn (or 
intestinal glands) and presenting goblet cells, which rests over a lamina propria 
bearing multiple lymphoid cells and individual lymph nodes (4). The lack of villi and 
microvilli provides a relatively small surface area for absorption as compared to the 
small intestine. Also, Paneth cells, the main producers of antimicrobial factors in the 
small intestine, are usually absent in healthy colon and rectum (5). Proximal to the 
pectinate line the simple columnar epithelium makes an abrupt transition to non-
keratinized stratified squamous epithelium (anorectal junction), which extents 
continuously towards the keratinized stratified squamous epithelium of the skin at the 
external anal sphincter (6). 
Blood supply and return are assured by rectal arteries and rectal veins, 
respectively (7). The superior rectal arteries irrigate the upper and middle rectum, 
while the middle rectal artery irrigates the lower rectum and proximal anal canal. The 
inferior rectal arteries supply the anus and the anal sphincters.  The venous drainage 
of the rectum and anus correlates to and travels with its arterial supply. The superior 
rectal vein drains the upper and middle rectum into to the portal vein. The venous 
blood of the lower rectum and anal canal is collected by the middle and inferior rectal 
veins and drains into the inferior vena cava. Thus, drugs absorbed at the lower 
rectum avoid, at least partially, the hepatic first-pass metabolism, reaching directly 
the systemic circulation. In contrast, drugs absorbed at the upper rectum undergo 
pronounced hepatic first-pass effect. Nevertheless, this relation is not straightforward 
as extensive anastomoses connect all three rectal veins throughout the rectum (7). 
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Figure 2.1. Schematic representation of the anatomy and histology of the human rectum: (A) 
gross anatomy and position of the rectum in relation to the colon and anus, (B) detailed 
longitudinal anatomy of the colorectum and anus, and (C) histology of the anorectal mucosa 
(longitudinal section, H&E stain, low magnification). Image in (C) reproduced from reference 
(4), Copyright (1999), with kind permission from Springer Science and Business Media. 
Legend: A, anus; Ac, anal canal; AC, ascending colon; Ap, appendix; ARJ, anorectal 
junction; AV, anal verge; BLV, blood and lymphatic vessels; C, cecum; DC, descending 
colon; ES, external sphincter; IG, intestinal glands (crypts of Lieberkühn); IHP, internal 
hemorroidal plexus; IS, internal sphincter; LAM, levator ani muscle; LC, lymphoid cells; LP, 
lamina propria; LR, lower rectum; MM, muscularis mucosa; MR, middle rectum; PL, pectinate 
line; R, rectum; RSJ, rectosigmoid junction; SC, sigmoid colon; SCE, simple columnar 
epithelium; SSE, stratified squamous epithelium; TC, transverse colon; TF, transverse folds; 
UR, upper rectum. 
 
 
 
Broad networks originating in the mucosa and submucosa give rise to lymphatic 
vessel. The lymph of the descending colon, sigmoid colon and upper rectum are 
collected by inferior mesenteric lymph nodes and drains into the left lumbar trunk. 
The lymph of the middle and lower rectum drains to internal and external iliac lymph 
nodes, which then converge to the lumbar trunk (8). The contribution of the lymphatic 
vessels for drug absorption is not well established since lymph flow is residual as 
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compared to blood circulation. However, lymphatic drainage may also allow avoiding 
the hepatic first-pass effect. 
The mucosal lining of the GIT is covered by a mucus layer which provides 
protection against mechanical stress (e.g., during defecation) and is an efficient 
barrier for xenobiotics and pathogens (9). Rectal mucus is mostly produced by goblet 
cells and composed mainly of water and mucins (5%), although presenting minor 
amounts of other components, namely antimicrobial factors like lysozymes, 
defensins, cathericidins and secretory phospholipase A2 (10, 11), some of which 
have been shown to inhibit HIV (12). The consistency of mucus is largely influenced 
by its content in mucins, which gradually increases along the colon and towards the 
rectum (13). The rectal fluid layer is around 150 m in thickness (range 75-250 m) 
(14), with an estimated turnover time of 3-4h as determined ex vivo using rectal 
biopsies (15). Mucus presents a slightly alkaline pH, around 7-8, with minimal 
buffering capacity (16). The total amount of fluid at the rectal cavity is estimated at 1-
3 mL (17). 
Another important issue to be considered is microbiota at the colorectal 
environment. The amount of microorganisms increases along the GIT and towards 
the colorectum, being mainly composed by anaerobic Gram positive and Gram 
negative bacteria, and constituting an important natural mechanism of defense 
against pathogens (18). However, the role of microbiota on the prevention of viral 
infections is poorly understood and some evidence points out that it can either 
protect or promote viral transmission and/or spread, through direct or indirect 
mechanisms (19). For example, the role of bacterial lipopolysaccharide in HIV 
replication or inactivation has been the focus of different studies, however, with 
inconclusive results (20, 21). Also of interest, rectal microbiota produce hydrolytic 
and reductive enzymes which can influence the metabolism of drugs (22).   
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2.1.2. Rectal drug delivery  
 
The administration of drugs into the rectum can provide a suitable way to 
produce either local or systemic effects, and constitutes mainly an alternative to other 
mainstream delivery routes, namely the oral one. A synopsis of the main advantages 
and limitations of the rectal route is presented in Table 2.1. The possibility of rectal 
delivery for different drugs (e.g., anticonvulsants, analgesics, anti-inflammatories, 
anti-asthmatics, antiemetics, antibiotics) has been studied and, in many cases, their 
use is well established in clinical practice. In particular, rectal delivery may be useful 
for managing colonic disease due to the short anatomical distance and continuum 
between these two sites of the GIT. Also, the systemic delivery of peptides and 
proteins through the rectal route has been under investigation but often with 
moderate success and requiring substantial formulation efforts (23, 24). The rectal 
mucosa may also constitute a potential site for vaccine administration in order to 
obtain topical and systemic immune responses against various microorganisms, 
including HIV (25). 
 
 
Table 2.1. Advantageous and disadvantageous features of the rectal drug delivery route. 
Advantages Disadvantages 
Non-invasive Erratic drug absorption 
Relatively stable environmental conditions (a) Absorption influenced by local pathologies 
Partial avoidance of hepatic first-pass effect Presence and traffic of stool 
Low enzymatic activity (b) Acceptability (cultural) issues 
Relatively high amounts of drug can be 
administered 
May cause irritation (c) 
May limit systemic exposure/adverse effects (c) May cause discomfort 
Rapid onset of pharmacological effect Defecation urge 
Allows self-administration Leakage 
May be used in unconscious subjects  
Not limited by emesis  
Suitable for pediatric and geriatric patients  
Painless  
(a) pH, amount of fluid, among others; (b) as compared to the upper GIT; (c) dependent on drug and drug product 
characteristics. 
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The relatively smaller surface area of the rectal mucosa, as compared to the 
small intestine, limits its absorptive capacity. Even so, rich blood and lymphatic 
drainage may allow obtaining significant systemic levels for different drugs. Some 
compounds can even have higher bioavailability upon rectal delivery as compared to 
the oral route due to the partial avoidance of the hepatic first-pass effect (26, 27). 
Drugs administered in the rectum require to be released from dosage forms and 
dissolve in local fluids in order to be absorbed (1). This process will influence the 
extension and rate of absorption and is dependent on multiple factors, namely: (i) 
local environment and health state (temperature, fluids characteristics – pH, volume, 
surface tension, viscosity, buffer capacity, thickness –, microbiota and host mucosal 
metabolism, presence of feces), (ii) host behavior and health state (defecation, 
involuntary expulsion, acceptability, constipation, local trauma, luminal pressure or 
periodic contractile activity of the rectal wall), (iii) drug properties (solubility, partition 
coefficient, particle size and surface, molecular weight – MW –, ionization degree, 
concentration), and (iv) dosage form/delivery system features (composition, melting 
point/dissolution ability of solid systems, surface tension, dielectric properties, 
rheological properties) (1, 2, 28). Once dissolved in the luminal fluid, drugs need to 
cross different barriers in order to reach the blood and/or lymph, such as the mucus 
layer, apical and basal cell membranes, tight junctions, basement membranes, 
intracellular compartments and walls of lymph vessels or blood capillaries (29). 
Rectal drug absorption occurs mainly by passive transport, and active molecules may 
be absorbed by the transcellular or paracellular pathways, depending on their 
physicochemical features (30). The transport by the first pathway is mainly for drugs 
with some degree of lipophilicity, and is well explained by the pH-partition hypothesis. 
According to this last, only non-ionized molecules of a compound will be available for 
diffusion across membrane lipids. The second is a common pathway for many water-
soluble and poorly lipid-soluble molecules as well as ionized drugs (30). 
Absorption can be a double edge-sword depending on the final intent of the 
administered drug (i.e., local or systemic action). In many ways, absorption depends 
on dosage forms/delivery systems used and can be modulated by changing the 
pharmaceutical formulation, namely by using absorption enhancers or enzymatic 
inhibitors (31). Drugs are usually administered in the rectum as liquid (solutions, 
suspensions, emulsions) – commonly referred to as enemas or microenemas 
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depending on volume –, semisolid (gels, creams, ointments) and solid (suppositories, 
capsules) dosage forms (32, 33). With the exception of solid ones, other dosage 
forms require the use of an applicator. Suppositories constitute most of current 
products administered rectally in clinical practice. The base composition of 
commercialized rectal products varies widely, conferring different properties that can 
change the degree and rate of drug release and absorption. So, the physicochemical 
characteristics of the drug and its desirable release pattern should be taken into 
account when excipients/dosage forms are chosen. For instances, the use of liquid 
dosage forms allows faster absorption since drug release and dissolution issues are 
generally circumvented (1). Drug absorption is slower when solid systems such as 
suppositories are used, although this is tremendously dependent on composition 
(28). The spreading features of a product are highly dependent on properties such as 
viscosity and mucoadhesion, and may determine the drug fraction bypassing hepatic 
first-pass metabolism and influence the effectiveness of drugs administered for local 
action. Overall, drugs administered as suppositories are confined to the rectum and 
sigmoid colon while enemas, depending on their volume, can reach more proximal 
portions of the colon. Foams seem to have an intermediary behavior between 
enemas and suppositories. Further, smaller volumes are linked with greater rectal 
drug retention, while volumes higher than 80 mL usually stimulate defecation (1). 
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2.2. Nanotechnology-based approaches for rectal drug delivery 
 
2.2.1. Role of nanotechnology in rectal drug delivery 
 
Nanotechnology is often seen with overwhelming optimism when considering 
healthcare applications, despite many well-known limitations and challenges (34). 
Beyond the common hipness and popularity associated with nanomedicine, there are 
actually several possible advantages of using nanocarriers that could be interesting 
for rectal administration of active compounds. Alongside data obtained from studies 
specifically addressing rectal administration of nanosystems, a set of possibilities can 
also be inferred from studies involving other drug delivery routes, namely the oral 
one. From a general perspective of pharmaceutical formulation, nanotechnology-
based approaches have been successful in solving poor drug solubility, which is 
known to undermine the use of various promising compounds (35). In the particular 
case of the rectal compartment, the low amount of fluids that are naturally present or 
that can be administered makes solubility a main topic to be considered. Relatively 
simple solutions such as nanosizing insoluble drugs may be useful. As an example, 
Rachmawati et al. (36) observed enhanced anti-inflammatory effects for D-α-
tocopherol PEG 1000 succinate (TPGS)-stabilized curcumin nanosuspension (mean 
particle diameter of 210 nm) after multiple rectal administrations to a trinitrobenzene 
sulfonic acid (TNBS)-induced colitis rat model, as compared to a curcumin 
suspension (>7 m and also containing TPGS). The use of drug nanocarriers can 
further be helpful in allowing the production of physicochemical stable systems 
containing labile compounds such as nucleic acids or proteins. Hard to formulate 
drugs may found in nanotechnology a suitable way to abbreviate degradation during 
storage and even upon administration in the lower GIT (37). Control of drug release 
is also possible with nanocarriers (38), even though other type of larger systems may 
be better suited for such purpose. 
The distribution and retention of drugs upon rectal administration are important 
factors in defining drug efficacy. Depending on specific colloidal properties, 
nanocarriers can help enhancing drug transport along and across mucus and 
coverage of the mucosal surface, as well as increase residence. This particular topic 
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has seen important advances over recent years and is discussed in more detail over 
the next section. Nanosystems present the additional potential for targeted drug 
delivery along the colorectum, particularly when diseased tissues can be 
distinguished from healthy counterparts (e.g., in ulcerative colitis (UC) or cancer) (39-
41). In these cases, distinct pathophysiological features of the mucosal wall can be 
used for engineering targeted nanosystems. For example, Lamprecht et al. (42) 
reported on the accumulation of negatively-charged polystyrene particles at inflamed 
tissue areas of the colon following deep intrarectal administration to rats presenting 
TNBS-induced colitis. Such effect could be moderately enhanced by simply reducing 
the size of the particles from 1 m or above to 100 nm. A clear mechanistic 
explanation for these observations was not provided but differences in bioadhesion 
as related to different properties of local mucus (thicker but possessing looser 
structure in colitis) and tissue charge (more positive in colitis (43)), as well as 
disruption of the epithelial barrier, may be involved. Indeed, differences between 
differently sized negatively-charged particles were not seen when considering normal 
colon mucosae, including in healthy rats (42). The presence of an abnormal number 
of immune cells in inflammatory conditions of the colon may also have contributed to 
the enhanced uptake of NPs and, thus, tentatively lead to increased drug 
concentrations at damaged tissues (44). Importantly, a first in-human trial testing 
either PLGA-based NPs (250 nm) or microparticles (3 m) failed to essentially 
replicate previous animal data (45). Particles were administered intrarectally in a 
normal saline enema containing 10% albumin, which was retained for 2 h in loco 
before expulsion, and further probed by confocal laser endomicroscopy. While larger 
particles, but not NPs, were shown to mildly target ulcerated tissue in inflammatory 
bowel disease (IBD) patients, accumulation was overall much lower. Although a more 
objective explanation for these discrepancies seems elusive, interspecies variability 
and substantial differences in the colloidal properties of particles (polymer type, size, 
surface charge, albumin coating) may be accountable. Again, proper engineering of 
nanosystems appears to be of paramount importance for overall performance. 
Targeting specific biological moieties that are naturally present at the 
epithelium by using functionalized nanocarriers may further be useful as a strategy 
for enhancing drug delivery, namely for cell targeting (46). Another interesting feature 
of nanosystems has to deal with the possibility of modulating drug permeability at the 
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colon and, thus, influence bioavailability. Nanoparticulate systems are able to actually 
penetrate colorectal tissue, which could be beneficial for allowing the establishment 
of a drug depot that sustains local drug residence, as well as for targeting structures 
or cells present at the lamina propria (47). Data from experiments using ex vivo 
human rectal mucosa biopsies obtained from healthy individuals and IBD patients 
indicate that translocation of negatively-charged PLGA-based NPs (250 nm) across 
intact epithelium is limited but increases in damaged mucosa (45). Limited evidence 
further suggests that at least some type of nanosystems, namely liposomes of 300 
nm in diameter, may partially reach systemic circulation upon rectal delivery and 
distribute throughout various distant tissues (48). However, recent work using PEG-
modified silica-based nanocapsules (120 nm) indicates that such absorption and 
long distance recovery of NPs is typically scanty following intrarectal administration 
(49). Lack of systemic exposure to nanosystems may be considered of interest as it 
may favors localized pharmacological action and reduced potential toxicity. 
Lastly, a note is due to nanosystems possessing intrinsic pharmacological 
activity rather than acting as drug carriers. Dendrimers, in particular, have been 
comprehensively tested for their potential use as rectal microbicides in order to 
prevent infection by multiple pathogens, including HIV (50-52). The colloidal nature of 
these structures allows enhancing exposure of surface chemical groups responsible 
for interactions with pathogen or host molecular targets involved in transmission. 
Silver NPs (53, 54) and glass beads coated with nanolayers of silver (55)  have also 
been studied for the treatment of colitis due to their intrinsic anti-inflammatory activity. 
 
 
2.2.2. Distribution and retention of nanosystems following rectal 
administration 
 
One of the potential advantages of using nanosystems has to deal with their 
ability to modulate self-distribution, as well as residence, along the terminal GIT. 
Transport in the colorectal lumen and beyond is conditioned by several factors 
related not only with the mucosal environment but also with the intrinsic 
characteristics of nanosystems such as size and surface chemistry. Indeed, as 
discussed in the following, suitable engineering of the colloidal features of 
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nanosystems plays a key role in modulating biodistribution upon rectal 
administration. 
As in the case of other type of materials, nanosystems typically undergo rapid 
depletion towards the exterior following administration in the rectum as a result of the 
natural bowel movement and defecation reflex. The presence of stool or practice of 
anal sex may additionally influence clearance. Moreover, retrograde transport is 
thought to be naturally limited, although different studies demonstrated that 
nanosystems can indeed reach far into the upper parts of the colon and feature more 
or less extended residence. For example, Zavaleta et al. (49) showed that surface-
enhanced Raman scattering (SERS) NPs (120 nm) – comprising gold core/silica 
shelled capsules modified at the surface with PEG (2-5 kDa) and 64Cu – distributed 
throughout the colon following rectal administration to mice, as assessed by Raman 
imaging and micropositron emission tomography. Although the depth of catheter 
insertion into the colon was not disclosed (but likely several centimeters) nor 
quantitative colon spreading studies were performed, data suggest that NPs could be 
transported retrogradely, at least in some animals (Figure 2.2) (49). The use of a 
relatively large volume (200 L) may aided spreading. Also, distribution into the blood 
and other organs (including the spleen and liver) was shown negligible. Another 
report by the same group confirmed these data and further indicated that NPs were 
rapidly washed out from the colon following a single rectal administration, without 
apparent signs of systemic toxicity (56). 
One particularly limiting physiological factor for colorectal distribution and 
retention is the presence of mucus, a viscoelastic gel composed of water and 
entangled mucin fibers, which constitutes a stringent barrier for particle diffusion (57, 
58). The ability of nanosystems to bond mucins determines their adhesive behavior 
and, thus, overall mobility. The use of mucoadhesive nanosystems has been 
conventionally considered beneficial for enhancing drug retention at mucosal sites 
and a popular approach to improve either local or systemic drug bioavailability (59). 
Strategies involving the modification of the surface of nanosystems in order to yield 
enhanced molecular entanglement and covalent or non-covalent bonding with mucin 
fibers are recognized for increasing mucoadhesiveness (60). However, strong 
adhesion of nanosystems to mucins impairs effective transport across mucus thus 
limiting distribution not only towards the underlying mucosal tissue but also 
Chapter 2 ǁ Literature Review 
21 
 
retrogradely into the colon. Also, mucoadhesive systems are mostly immobilized at 
the outer, non-adherent layer of mucus, which undergoes continuous and rapid 
clearance (57, 61). 
 
 
 
Figure 2.2.  Micropositron emission tomography images of the accumulation of 64Cu-
modified SERS nanoparticles post intravenous (IV) injection (top panel) versus post 
intrarectal (IR) injection (bottom panel). The images represent a coronal slice of a single 
mouse taken at various time points; immediately, 30 min, 2 h, 5 h, and 24 h after either IV or 
IR injection. Notice the significant difference in the accumulation of 64Cu-modified SERS 
nanoparticles in mice receiving an IV injection, where uptake is localized to the liver, versus 
mice receiving an IR injection, where uptake is localized to the colon. Colored scale bar to 
the right of each image represents 64Cu-SERS uptake where red represents most uptake and 
black represents no uptake in units of percentage of injected dose per gram (%ID g−1). 
Reprinted with permission from (62). Copyright (2011) Wiley-VCH Verlag. 
 
 
 
Conversely, mucus-diffusive (or mucus-penetrating) nanosystems can migrate 
to the inner layer of mucus, which is less prone to luminal shearing, and even have 
easier access to underlying tissues. Therefore, the use of non-mucoadhesive 
nanosystems has been gaining advocates over recent years as an interesting 
approach to promote not only spreading along mucosal sites but also enhance 
overall residence (63, 64). The most successful strategy for producing mucus-
diffusive nanosystems has been developed by Hanes and collaborators (65-67) and 
involves dense surface modification of nanosystems with PEG featuring adequate 
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molecular mass for preventing interactions with mucin, alongside adequate particle 
size control down to dimensions that allow fitting the mucus mesh spaces. Still, other 
approaches have also been recently proposed including surface modification of 
nanosystems with alternative non-mucoadhesive polymers or association with 
mucolytic agents (68-71). In the specific case of rectal delivery applications, Maisel et 
al. (72) modified polystyrene NPs of different sizes with PEG (5 kDa) and found that 
this approach led to an overall increase in migration of nanosystems across mucus, 
as well as to an extensive coverage of the epithelial surface after administration to 
mice (Figure 2.3). Contrariwise, mucoadhesive counterparts (i.e., without PEG 
modification) distributed poorly and largely aggregated at the intestinal lumen. Size of 
NPs also played an important role: 40-100 nm PEG-modified NPs featured a more 
uniform distribution along the epithelial surface as compared to larger ones (200-500 
nm). This fact may well be associated to the available space within the colorectal 
mucus mesh, which sterically hinders transport of larger nanosystems. Another 
important finding of this study relates with different patterns of NPs transport due to 
pathological changes. For example, colorectal distribution of 200 nm mucus-diffusive 
NPs was enhanced in a TNBS-induced colitis mouse model, which feature a thicker 
yet looser mucus barrier, as compared to healthy animals. Moreover, mucus-diffusive 
NPs appeared to accumulate better than mucoadhesive counterparts in ulcerative 
lesions (72). The use of a hypotonic vehicle was further shown beneficial for 
administering mucus-diffusive NPs due to the promotion of convective transport (72, 
73). In a subsequent study by the same research group, similar behavior was also 
described for NPs modified with PEG of higher molecular mass (40 kDa) after 
intrarectal administration to mice (74). Despite these interesting findings, actual time-
dependent, quantitative retrograde migration and overall colon retention of PEG-
modified NPs were not determined. Assessment of such data is paramount for fully 
understanding the potential of mucus-diffusive NPs as carriers for rectal drug delivery 
and, thus, additional investigation is required. 
 
Chapter 2 ǁ Literature Review 
23 
 
 
Figure 2.3. Trajectories in colorectal mucus and distribution of mucoadhesive particles 
(MAP) and mucus-penetrating particles (MPP) in the mouse colorectum. Trajectories 
representative of three seconds of movement for 40, 100, 200, and 500 nm MAP and MPP in 
mucus on freshly excised mouse colorectal tissue as assessed by multiple particle tracking 
video microscopy. Black scale bars indicate 1 m for all trajectories. Distribution in 
transverse colonic cryosections after rectal administration of 40, 100, 200, and 500 nm MAP 
(red) or MPP (green). Cell nuclei are stained with DAPI. White scale bars indicate 300 m for 
all distribution images. Images are representative of n ≥ 3 mice. Reprinted from (72), 
Copyright (2014), with permission from Elsevier. 
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2.3. Rectal transmission of HIV  
 
Understanding the pathogenesis of HIV transmission through mucosal 
surfaces, namely the rectal mucosa, is crucial for the development of rectal 
microbicides. Despite all efforts undertaken since the discovery of the virus, there are 
still some loose ends regarding the understanding of the complete mechanism of 
rectal infection. Transmission is mediated by HIV-target cells (i.e., T cells, macro-
phages and dendritic cells) present at the lamina propria of the mucosa after rectal 
deposition of semen containing cell-free or cell-associated virions (Figure 2.4) (75). 
In vivo evidence seems to point towards cell-free virus as being the most important 
source for infection (76), even if recent animal studies showed that cell-associated 
virus (simian immunodeficiency virus – SIV) may be more efficiently transmitted (77, 
78). Once in the rectum compartment, HIV appears to take advantage of multiple 
mechanisms to overcome the epithelial barrier and achieve target cells (Figure 2.4, 
A-E). For example, the presence of micro ulcerations or mechanical breaching, 
frequently resulting from sexual intercourse, provides a direct access to the lamina 
propria. The occurrence of concomitant infections, namely by herpes simplex virus 
type 2 (HSV-2) (79) or human papillomavirus (HPV) (80), or the presence of HIV 
virions (81) can also induce epithelial damaging and target-cell recruitment. The virus 
can even cross intact rectal epithelium by transcytosis through epithelial cells (82) or 
be taken up by microfold cells (M cells) overlaying lymphoid follicles  (83). Also, 
transmission can occur via dendritic cells as mediated by a trans-infection 
mechanism involving dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) (84).   
Overall, only a very small number of events are required for the virus to reach 
target cells at the lamina propria. These cells typically express the cluster of 
differentiation  4 (CD4) receptor, which render them susceptible to viral infection, and 
at least one of two co-receptors, C-C chemokine receptor type 5 (CCR5) and C-X-C 
chemokine receptor type 4 (CXCR4), even if CCR5-tropic (R5) viruses are more 
efficiently transmitted and account for most of the HIV primary infections worldwide 
(85). After the establishment of a founder population of HIV-infected cells and its 
mucosal expansion, viral dissemination to nearby lymph nodes and then to 
Chapter 2 ǁ Literature Review 
25 
 
secondary lymphatic tissues occurs, with consequent establishment of irreversible 
systemic infection (86). 
 
     
 
 
Figure 2.4. Schematic representation of the possible mechanisms for HIV transmission 
across the colorectal mucosa. The virus can access the underlying lamina propria by (A) 
epithelial transmigration of HIV-infected cells, (B) direct access of the free virus through 
physical breaches in the epithelium, (C) transcytosis of HIV across epithelial cells, (D) 
transcytosis of the free virus across specialized microfold cells (M-cells), or (E) binding of 
HIV to dendritic cells (DC) followed by non-endocytic transfer. Once at the lamina propria, 
the virus is presented to target cells and undergoes local amplification before systemic 
dissemination of the infection. 
 
 
 
Notably, increased risk of HIV acquisition through URAI as compared to the 
vaginal route can be explained, at least partially, by anatomical, physiological, 
immunological and histological features (87). For example, the near neutral pH and 
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minimal buffer capacity of rectal fluids provide no to little protection against infection, 
contrasting with the acidic pH of the vagina conferred mostly by microbiota-produced 
lactic acid, which is able to protect against sexually transmitted pathogens including 
HIV (88). The simple columnar epithelium of the colorectal mucosa turns this natural 
barrier more vulnerable to physical damaging during sex, thus increasing the 
likelihood of the virus to reach target cells (89). Contrasting with the vaginal mucosa, 
lymphocytes in colorectal tissues are constitutively activated, thus increasing viral 
susceptibility (90). Furthermore, the open ended structure of the rectum provides a 
greater surface area for infection as compared with the vaginal cavity. Some studies 
have been conducted to establish the potential distribution of semen/HIV particle 
surrogates in the GIT following rectal administration in humans (91-93). Although 
these studies indicate that the rectum and sigmoid colon are most likely to be the 
sites where HIV is retained, semen/viral surrogates could still reach as far as the 
splenic flexure (transverse colon to descending colon transition). Cell-free and cell-
associated surrogates also appear to have similar distribution patterns (93). Still, a 
recent investigation by McElrath et al. (94) suggests that the rectum may be more 
susceptible to HIV infection than the colon due to the increased expression of the 
CCR5 co-receptor on rectal macrophages as compared to those in the colon. These 
findings were further supported by another study (95), which defined a dominant 
macrophage population expressing DC-SIGN in human colon and rectum. Moreover, 
lymphoid nodules are in higher numerical density in the rectum than elsewhere in the 
large intestine, thus reinforcing the higher susceptibility of the rectum to HIV 
transmission (96).  
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2.4. Rectal microbicides  
        
2.4.1. Past and current status 
 
The past twenty years of microbicide research have been mainly focused on 
the prevention of vaginal heterosexual HIV transmission. Indeed, rectal microbicide 
development has been in the shadow of vaginal microbicides but increasing HIV 
infection numbers among MSM over recent years, evidence of higher rates of 
transmission through the rectal route, and the noticeable interest of MSM in the 
concept of microbicides triggered an increasing awareness of the field (97). Of 
course, data obtained from vaginal microbicide studies has been of undeniable 
relevance and provided a solid ground for the development of rectal products. It is 
not surprising then that most of the products tested so far as rectal microbicides have 
been previously evaluated for preventing vaginal HIV transmission. 
First pre-clinical studies were mainly focused in the safety assessment of non-
specific microbicides developed for vaginal use, namely products containing 
nonoxynol-9 (N-9) (98, 99). N-9 is a non-ionic surfactant still used as an over-the-
counter (OTC) vaginal spermicide and one of the first vaginal microbicide candidates. 
Its possesses a non-specific mechanism against HIV leading to viral disruption (100). 
The first rectal microbicide Phase 1 clinical trial – the HIV Network for Prevention 
Trials (HIVNET)-008 study – was conducted with a N-9 gel and studied not only its 
safety but also acceptability (101, 102). However, poor effectiveness results for this 
compound when tested as a vaginal microbicide, including the ability to enhance viral 
transmission (103), discouraged further development of N-9 products as rectal 
microbicides. Led by these disappointing outcomes, safety became emergent in the 
field and is now considered a go-no-go condition. Again, following the storyline of 
vaginal microbicide candidates, other surfactants (e.g., C31G) (104), buffering agents 
(e.g., BufferGel) (105) and polyanionic sulfated polymers (e.g., PRO 2000, cellulose 
sulfate, carrageenan) (50, 106) have also been tested in pre-clinical studies as rectal 
microbicides but with little success and, again, suffering from poor results of these 
candidates in vaginal microbicide clinical trials (107-110). 
Chapter 2 ǁ Literature Review 
28 
 
From these disappointing results with early-generation unspecific candidates, 
the field of microbicides moved towards the use of potent ARV agents, much like 
those used in therapy (100). These compounds present high specificity against HIV, 
thus potentially being active at levels where toxicity to epithelial barriers and local 
microbiota are lower. The promising results of the Phase 2b CAPRISA 004 trial 
testing a 1% tenofovir (TFV) vaginal gel established in human proof-of-concept for 
microbicides (111) and boosted research in ARV drug-based microbicides, not only 
for vaginal but also for rectal use. Different ARV drug classes are being tested in vitro 
for their ability to protect rectal tissue explants from HIV infection, namely fusion 
inhibitors (e.g., L´644 (112)), reverse transcriptase inhibitors (RTI; e.g., TFV, UC781, 
dapivirine (113-115)) and protease inhibitors (e.g., saquinavir (116)), either alone or 
in combination. Paralleling current ARV drug therapy, some microbicide 
combinations have been proved more potent than single drug use while allowing 
reducing the possibility of drug resistance, thus reinforcing the potential benefit of 
combination rectal microbicides (114, 117). Furthermore, various candidates have 
moved into non-human primate (NHP) studies and compounds such as cyanovirin-N 
(118), maraviroc (MVC) (119, 120), TFV (120, 121) and MIV-150 (122, 123) 
formulated as rectal gels were found safe and effective in preventing SIV or 
simian/human immunodeficiency virus (SHIV) transmission upon rectal challenge. 
Although humanized mice models have been less frequently used, the efficacy of 
rectally-applied MVC gel (124) and 1% TFV in phosphate buffer saline (PBS) (125) 
was also demonstrated using these models. More recently, a humanized mice model 
was also used to ascertain the intrarectal drug dose of TFV disoproxil fumarate (TDF) 
and emtricitabine (FTC) required to provide protection against HIV transmission 
(126). 
Two Phase 1 clinical trials have been performed in order to test gel products 
containing either 0.1% or 0.25% UC781 (RMP-001 study) (127), or 1% TFV (RMP-
02/MTN-006 study) (128), which have been previously tested as vaginal microbicides 
(Table 2.2). In the case of the UC781 gels, formulation issues dictated the premature 
ending of the clinical development of this compound; as for the 1% TFV gel, the 
RMP-02/MTN-006 study showed that the formulation previously tested for vaginal 
administration was not completely safe or even acceptable for rectal use, thus 
stressing the need for specific formulation of rectal microbicide candidates. A 
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subsequent Phase 1 study (MTN-007) testing a reduced glycerin version of the 1% 
TFV gel showed that the new product was safe and acceptable for rectal use (129).  
Following the encouraging results of the MTN-007 study, a Phase 2 clinical 
trial (MTN-017) was conducted (130). In MTN-017, participants were enrolled to each 
of three regimens for eight weeks: daily reduced glycerin 1% TFV gel, reduced 
glycerin 1% TFV gel before and after sex, and oral TDF/FTC (Truvada®). Both rectal 
regimens presented similar safety profiles when compared to oral TDF/FTC. 
However, results for adherence and product use likelihood were favorable for the 
intermittent rectal gel and daily oral PrEP, while daily use of rectal gel was less 
acceptable. 
Also, the Combination HIV Antiretroviral Rectal Microbicide (CHARM) program 
was set to develop and evaluate both single and combination ARV compounds as 
rectal specific microbicides. Two Phase 1 studies, CHARM-01 and CHARM-02, 
assessed the safety, acceptability, PK/pharmacodynamics (PD) correlation and 
distribution of the original (vaginal) 1% TFV gel, the reduced glycerin 1% TFV gel, 
and a rectal specific 1% TFV gel. Overall, both formulations of reduced glycerin 1% 
TFV gel and rectal specific 1% TFV gel were found safe and acceptable. The original 
1% TFV vaginal gel was associated with minor adverse effects, higher systemic drug 
exposure and higher colonic distribution when compared to the other two 
formulations. This last phenomenon was explained by the higher osmolality of the 
vaginal TFV gel, which was implicated in higher fluid drawing to the colonic lumen 
and thus allowing the upwards gel spreading, as assessed by SPECT/CT (131, 132). 
A third study, CHARM-03, assessed the safety, acceptability and PK/PD 
profile of both oral MVC and a rectal specific MVC gel (133). The results were not yet 
released but preliminary data revealed that both oral MVC and the rectal specific 
MVC gel were found safe and well tolerated. However, both products were ineffective 
in preventing viral infection in colorectal explants (134). The Project Gel study 
investigated rectal microbicide safety, adherence, and acceptability in young MSM 
from ethnic minorities (135). Firstly, participants tested a placebo gel during RAI in an 
acceptability and adherence trial. Next, safety of reduced glycerin 1% TFV gel and 
matched placebo were assessed. Once again, this study confirmed the safety and 
acceptability of reduced 1% TFV gel among these men. 
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Table 2.2.
clinical trials.
Microbicide 
product
0.1% or 0.25% 
(w/w) UC781 
gel 
1% (w/w
gel 
Reduced
glycerin 1% 
(w/w) TFV gel
Rectal-specific 
1%  (w/w
gel 
(a) Concentrations are indicated in brackets if available; N.A. 
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e products used in completed or ongoing rectal microbicide 
Excipients (a)
Carbomer 974P,  methylcellulose, 
glycerin, purified water, 
methylparaben, propylparaben
Glycerin (20%),  
hydroxyethylcellulose (2.5%), 
methylparaben (0.18%), 
propylparaben (0.02%),  
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ethylenediaminetetraacetic acid 
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study will evaluate the safety and acceptability of a rectal dapivirine gel (0.05%) in 
healthy HIV-uninfected men and women (139). In another Phase I study, MTN-033, 
the same dapivirine gel will be administered intrarectally using a vaginal applicator or 
a phallic device and the PK of dapivirine will be assessed (140). MTN-035 study will 
test the acceptability, tolerability and adherence of tentative placebo rectal 
microbicides administered to young MSM and transgender women in three different 
dosage forms: a rectal douche, a fast-dissolving rectal tablet and a rectal suppository 
(141). A Phase I clinical trial, MTN-037, will assess the safety and PK of a rectal gel 
that combines MIV-150 and zinc acetate in a carrageenan gel. This gel was designed 
to be used as a dual compartment (rectal and vaginal) gel in order to protect against 
HIV-1, HSV-2 and HPV (142). Finally, The Phase I clinical trial MTN-039 will evaluate 
the safety and PK of an insert containing elvitegravir after administration to men and 
women engaged in RAI (143). 
 
 
2.4.2. Formulation considerations and product design 
 
The main purpose behind the formulation of rectal microbicides is to provide 
adequate vehicles that can properly deliver an active pharmaceutical ingredient (API) 
to the site of action for a defined period of time in order to elicit protection from HIV 
infection. The development of rectal microbicides is supported by preformulation 
studies common to the development of most medicines, with the objective of 
characterizing APIs, namely regarding: (i) purity, (ii) physical and chemical properties 
(solubility, crystallinity, melting point, MW, particle size and shape, hygroscopicity 
and water content, acid/base ionization, polymorphism, mechanical behavior, etc.), 
(iii) organoleptic properties (color, odor, taste), (iv) stability in different states (dry, 
dispersed, dissolved) and at different pH values, (v) forced degradation studies under 
extreme conditions (light, heat, pH, oxidative stress), (vi) compatibility studies with 
excipients/materials and/or other APIs, among others (144). The previous is not an 
exhaustive list and may not be applicable to all compounds. At the same time, 
additional properties may be required depending on API. Further, the obtention of 
data specifically related with microbicides (e.g., solubility and stability in anogenital 
biological fluids and tissue homogenates) might also be pursued (145). 
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The combination of antiviral drug candidates with different excipients should 
allow producing safe, effective, stable and acceptable drug products. Some 
formulation development algorithms have been developed to guide microbicide 
formulation, but are mainly concerned with vaginal application (146-148). Indeed, the 
development of such rectal microbicide formulations remains challenging and it is 
difficult to detail on the ideal product. Nevertheless, there are different aspects of 
formulation that appear to be critical and are detailed in the following. 
 
 
2.4.2.1. Rectal lubricants and rectal drug products: lessons learned  
 
The use of OTC lubricants during sexual intercourse is a common and 
frequent practice among both men and women, particularly in populations engaging 
in URAI (149, 150). In some cases, namely in regions where access to these 
products is limited, other fluids (e.g., saliva, egg white, yoghurt, soft paraffin) have 
also been used as surrogates (151). These practices are easily understandable as 
the rectum does not self-lubricate before or during intercourse, contrasting with the 
vagina. Hence, lubricants allow for more comfortable and non-traumatic anal sex. 
The concomitant use of lubricants and male condoms may also be beneficial since 
decreased breakage rates (around 7-fold less than for no lubricant) have been 
reported (152). 
The wide use and potentially protective effects of these products (i.e., due to 
decreased shear during intercourse) provide an important rationale for the 
development of rectal microbicides and may even facilitate their future acceptance if 
formulated as lubricant-like products. Indeed, commercially available vaginal 
lubricants have been considered in the past as favorable vehicles for the 
incorporation of microbicide drugs. The Food and Drug Administration (FDA) does 
not regulate lubricants as medicines but as medical devices, thus excusing most of 
the extensive pre-clinical and clinical testing required for drug products (153), 
similarly to the European Medicine Agency (EMA). Lack of strict regulation is also 
noticeable in other regions of the world and, thus, performance of lubricants, 
particularly their safety, is not fully known (154). Even so, data deriving from recent in 
vitro and in vivo studies of lubricants provided important hints on the desirable 
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attributes of rectal products and, more important, perils related with the influence of 
formulation issues on the enhancement of HIV transmission and that should be 
considered when developing microbicide products (155, 156). Several of these 
aspects are addressed further in this manuscript. Of particular importance is safety 
namely due to the potential long-term use of a rectal microbicide product. Products 
containing N-9 were frequently used by MSM for their lubricant ability, being 
inclusively considered early on as potential rectal microbicide candidates (157). 
However, studies conducted with N-9 OTC products demonstrated the transient but 
potential hazardous effects of this detergent, namely rectal epithelial damaging 
(Figure 2.5) and consequential enhancement of HIV transmission (158), much in line 
with what had been previously demonstrated for its vaginal use (103, 159). 
Alongside N-9, other ingredients frequently present in lubricant products (e.g., 
polyquaternarium-15, clorohexidine) may have the potential to increase HIV 
replication as demonstrated in vitro (160, 161). Some lubricants may also deplete 
native microbiota, thus compromising the integrity of this potentially helpful barrier 
against pathogens. Further, differences in the colorectal and female genital safety 
profiles of some lubricants have been shown in vitro (161). These observations 
reinforce that specific rectal microbicide products are required and translation from 
vaginal data is not advisable. 
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Figure 2.5. Representative photomicrographs of rectal lavages and biopsy specimens of 18 
participants at different time points (15 min, 2 h and 8 h) following rectal application of a 2% 
N-9 gel (K-Y® Plus, Ortho-McNeil-Janssen Pharmaceutical). All samples were stained with 
toluidine blue and images taken at 96 magnification. (1) Rectal epithelium in lavage 
specimen collected 15 min following insertion of the N-9 gel, revealing sheets of gut 
epithelium composed of columnar and goblet cells. (2) Degraded cells in lavage specimen 
taken 2 h post N-9 gel insertion. (3) Baseline biopsy of rectal epithelium showing the typical 
simple columnar epithelium forming crypts of Lieberkühn and presenting goblet cells. (4 and 
5) Biopsies collected 15 min post-insertion of N-9 gel and evidencing some areas where the 
epithelium was separated, or partially separated, from the underlying submucosa (4); in 
some biopsies the epithelium directly opposed to the rectal lumen was not present (5). (6 and 
7) Biopsies collected 2 h post N-9 treatment and showing intact epithelium. (8) Biopsy taken 
8 h post N-9 treatment evidencing indistinguishable tissue architecture from that of baseline. 
Reprinted with permission from reference (158), Copyright (2004), with permission from 
Elsevier. 
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2.4.2.2. Dosage forms 
   
The rectal administration of pharmacological agents can be achieved by using 
several dosage forms as noticed above. However, only a few have been explored for 
developing rectal specific microbicides, namely suppositories, gels and enemas. 
Hydrophilic gels seem to be preferred by formulation developers as these are easily 
manufactured and affordable, despite potentially having stability problems and limited 
incorporation ability of hydrophobic compounds (162). Enemas share basic 
characteristics with gels, being consistency their most striking difference. The choice 
of this liquid dosage form is intimately related with the popularity of rectal douching 
among MSM engaging on RAI prior to or following sexual intercourse (163-165). 
Suppositories have a long history of rectal usage for drug delivery but acceptability 
problems related with cultural issues and misconceptions may undermine their 
widespread use (166). Despite being solid dosage forms with low water content, 
which may abbreviate drug stability issues, they are often designed to melt at body 
temperature by mixing excipients with different melting temperatures. However, their 
storage may be troublesome in tropical or otherwise hot regions of the globe where 
microbicides are most needed. 
Gels, in particular, enjoy good acceptance among users despite 
disadvantages such as product leakage and messiness upon administration, 
requiring an applicator for delivery, and coital dependence (167). For instances, 
Carballo-Diéguez et al. (168) compared the acceptability of a lubricant gel inserted 
using an enema bottle (35 mL per administration) versus a 8 g non-medicated 
suppository (Figure 2.6), used in up to three RAI occasions by 77 MSM. Overall, 
preference ratings for the gel were far superior to those for the suppository as 
perceived by both the participants and their partners. However, the large size of the 
studied suppository may have influenced acceptability, suggesting that smaller 
formulations, closer to those commonly used in therapy (2-3 g), may be preferable. 
Previous lubricant use patterns were not assessed, which could have introduced 
some bias in the overall appraisal of obtained results. In a more recent study 
enrolling males and females engaged in URAI, Pines et al. (169) assessed the 
acceptability of three OTC rectal products formulated as distinct dosage forms: (i) a 
solution filled in an enema bottle (Normosol®-R, Hospira, Inc., 125 
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mL/administration), (ii) a lubricant gel  (Pre-Seed®, Lil' Drug Store Products, Inc., 4 
mL/administration) delivered using a pre-filled vaginal applicator, and (iii) a 
suppository (Tucks™, McNEIL-PPC, Inc., 1.4 g/administration) commonly used in 
hemorrhoids relief. The lubricant gel scored higher overall acceptability rates as 
compared to the other two dosage forms, namely the small size suppository. 
Previous experience with lubricant gels (over 85% of participants), however, may 
also help explaining obtained results. 
 
 
Figure 2.6. Placebo products used in the acceptability study by Carballo-Diéguez et al. 
(168). (A) Lubricant gel in an enema bottle and (B) suppository (“rectal rocket”). Scale bars in 
images are in inches (1 inch=2.54 cm). Reprinted with permission from reference (168), 
Copyright (2008), with permission from British Medical Journal Publishing Group.  
  
 
 
2.4.2.3. Choice of excipients   
  
Besides functional properties related with specific dosage forms, excipients 
used in the formulation of microbicides need to ensure maximum activity and stability 
of APIs, while presenting no significant toxicity at used amounts/concentrations. Most 
of the products tested in clinical trials as rectal microbicides, and therefore their 
excipients, have been directly transposed from those used for vaginal administration 
(Table 2.2) (127-129, 136). Also, the choice of excipients for microbicide formulation 
has been traditionally based on functionality rather than safety, and mostly based on 
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past experience of their use in rectal drug products. Many of these excipients are 
included in the FDA “Inactive Ingredient Database”, as well as used concentrations 
according to the route of administration and/or dosage form. However, the relevance 
of these data is limited since it is based on products used with therapeutic purposes 
and usually for short-term usage, contrasting with the preventive aim and potential 
long-term usage of rectal microbicides. Also, the inclusion of an excipient in this list 
does not immediately rules out toxicity issues. The attention of regulatory agencies is 
indeed focused on the safety of products and excipients used in therapeutic products 
(170). Further, FDA guidelines for the safety evaluation of excipients seem to be very 
broad in order to adequately attest the suitability of an excipient for rectal microbicide 
formulation (171). 
Most preclinical safety/toxicity studies have focused mainly on APIs or the 
overall product formulation, while the evaluation of the toxicity of single excipients for 
rectal microbicides has been mostly neglected. For example, carbomers are popular 
and quite useful hydrophilic gelling agents in the formulation of rectal products (172). 
Despite being considered non-toxic and non-irritant excipients, with a long-term 
record of safety (173), Abner et al. (50) showed that a placebo carbomer-based gel 
caused a reduction of roughly 43% on the viability of human colorectal explants, 
contrasting with the low toxicity of hydroxyethylcellulose (HEC) and methylcellulose 
placebo gels. Even if relevant, the previous results may have been influenced by the 
presence of other excipients, in various degrees, thus limiting the usefulness of 
obtained data.      
 Ethylenediaminetetraacetic acid (EDTA) is often used in rectal microbicide 
formulation (Table 2.2). Despite that, this chelating agent has been previously shown 
associated with enhanced  HIV-1 replication in ectocervical explants (161) and HSV-
2 vaginal infection in  mice in a dose dependent manner (174). In the case of rectal 
use, it is known that EDTA allows increasing drug permeability (175), presumably 
due to calcium chelation and impairment of intercellular tight junctions as observed in 
vitro (176). Although the effects of such events on HIV transmission cannot be 
directly inferred, such potential epithelial barrier disruption may be deleterious. 
Further, EDTA showed to be toxic to the colorectal Caco-2 cells at concentrations of 
20 nM and 50 nM, with a decrease of 76% and 52%, respectively, on cell viability 
after 6 hours of exposure to this absorption enhancer (177). Nevertheless, a recovery 
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back to 93% and 82% on cell viability, respectively, was observed 24 hours after 
replacement of EDTA solution by fresh culture medium. 
Suppository bases are generally regarded as safe, including for pediatric use 
(178), but the specificities of rectal microbicides may limit their use in the formulation 
of safe preventive products. Again, very few data are available and extensive work is 
required. For instances, different commercially available mixtures of glycerides 
(Witepsol® H15, H12 or H19, and Suppocire® AP), and PEG have been shown to 
affect mucosal integrity upon rectal delivery to rats (179, 180). Moreover, while the 
effect of some bases was reversible after 24h (e.g., Witepsol® H15), mucosal 
damaging was further exacerbated by others after this time period (e.g., PEG 
1540/6000). In another study using a rabbit model, researchers also showed that 
PEG- and triglyceride-based materials caused irritation of the rectal mucosa after 
subchronical exposure, whereas monoglyceride- or fatty acid-based materials were 
less irritating (181). 
While the impact of excipient toxicity on HIV transmission or other pathogens 
infection may not be easily inferable, it seems reasonable that this matter should be 
considered and preliminarily tested as some compounds have been demonstrated to 
enhance rectal penetration or absorption of viral particles. For example, PEG 
monohexadecyl (or cetomacrogol 1000), a non-ionic surfactant used in suppository 
formulations, was shown to increase the absorption of Felix virus from the rectum of 
healthy rabbits (182). Overall, the above presented examples emphasize the 
necessity of toxicological evaluation of excipients intended for microbicide use and, 
ideally, the establishment of a specific database of safe (and hazardous) ingredients. 
 
  
2.4.2.4. Volume to be administered  
  
There is no standard for the amount of a liquid or semisolid microbicide 
product that should be administered rectally. The same applies to dosage forms that 
liquefy upon delivery (e.g., fatty base suppositories). The volume should be enough 
to protect the entire area that may potentially be used for HIV transmission, while 
abbreviating safety issues and being acceptable by users. Values around 3.5-4.0 mL 
arising from clinical practice (where only lower rectum action or absorption is usually 
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desired) and vaginal microbicide trials have been frequently used in the clinical 
testing of rectal microbicide gels (127-129). However, recent studies suggest that a 
rectal microbicide should cover the entire rectosigmoid and descending colon, ideally 
up to the splenic flexure, in order to provide complete protection against HIV (91-93, 
132). Achieving these distances will definitely require for higher volumes of a gel or a 
liquid, eventually in the order of those administer as enemas for IBD treatment (40-
100 mL) (33). However, two studies conducted by Hendrix and colleagues (91, 92) 
evidenced that volumes as low as 10 mL of a lubricant gel (K-Y® Jelly, Johnson & 
Johnson) were able to successfully reach the sigmoid and the descending colon in 
humans (Figure 2.7). The administration of the gel was followed by simulated anal 
intercourse with an artificial phallus, which may have also contributed to the observed 
distribution of the gel. Nevertheless, and since rheological properties of different 
products (including their dilutions with rectal fluids) may influence spreading and 
distribution patterns, as previously described for vaginal microbicides (183), these 
volumes should be seen as merely indicative. More recently, the same group showed 
that 3.5 mL of radiolabeled (1 mCi 99mTc-DTPA) universal placebo hydroxyethyl 
cellulose gel was able to provide similar surface coverage as a higher volume (10 
mL). Both volumes were well tolerated and high acceptability levels were reported 
(184).  
Another human trial showed that 125 mL of a isoosmolal enema (Normosol®-
R; 295 mOsm/kg) had a greater distribution and tissue retention pattern when 
compared to hyperosmolal (Fleet® Phosphate, Fleet Laboratories; 2,100 mOsm/kg) 
or hyposmolal (distilled water; 0 mOsm/kg) enemas as evaluated in the same study. 
The isoosmolal enema distributed through the distal colon and in some cases 
reached the splenic flexure, whereas the hyperosmolal was confined to the 
rectosigmoid (185). Water uptake or exudation by the mucosa as determined by 
electrolyte concentration may be implied in these findings.  
As acceptability is concerned, a single study conducted by Carballo-Diéguez 
et al. (186) assessed the influence of escalating volumes (5-50 mL) on the 
willingness of twenty men engaged in URAI to use a lubricant originally intended for 
vaginal administration (FemGlide®, Coopersurgical, Inc). These researchers found 
that up to 35 mL of gel were acceptable to the majority of participants, although 
smaller volumes were preferred (only 5 mL were completely acceptable). Increased 
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leakage and messiness were reported beyond 35 mL. Further, perceived comfort 
was variable when the gel was used with or without sexual intercourse. In the case of 
enemas, the volume of 125 mL of the isoosmolal enema aforementioned was overall 
accepted by the subjects included in this group (n=9). Therefore, an ideal rectal 
microbicide product should allow being administered in a relatively wide range of 
volumes while maintaining safety and efficacy. 
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Figure 2.7. Representative spatial distribution of a microbicide surrogate in the lower GIT 
upon rectal administration (92). The participant received 10 mL of the commercially sexual 
lubricant K-Y® Jelly labeled with 100 nm 99mTc particles, followed by simulated intercourse 
with an artificial phallus. Single photon emission computed tomography (SPECT) and 
computed tomography (CT) imaging was performed at different time points after 
administration. The microbicide surrogate migrated in a retrograde fashion into the 
rectosigmoid colon. At 4 h post-administration, imaging signal was evident at the distal 
descending colon, reaching the splenic flexure 24 hours later. This distribution pattern was 
observed for two other subjects using magnetic resonance imaging (MRI). (A) SPECT/CT 
fusion imaging. The microbicide surrogate is shown in blue. The co-registered CT image is in 
grayscale. In each panel, the coronal section is on the left, the sagittal section in the middle 
and maximum intensity projection (SPECT only) in the coronal plane on the right. (*) 
indicates radiotracer on body surface used for anatomical reference. (B) Random samples 
(1,000) taken from each SPECT image and plotted in three dimensions. The blue-green-
orange color shows the signal intensity in increasing order. The red curve shows the center-
line found through 3-D curve fitting [green = left (sagittal); yellow = back (coronal); dark 
yellow = bottom (transverse)]. Scale changes with each scan to maximize detail. Adapted 
from (92), Copyright (2012), with permission from the British Pharmacological Society. 
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2.4.2.5. pH and buffer capacity  
 
Fluids present in the rectum of healthy individuals are known to possess pH 
close to neutrality and low buffer capacity (16) and, hence, administration of a 
product may significantly impact final proton activity. Variations in pH can impact drug 
absorption and, most importantly, extreme values may potentially lead to irritation, 
discomfort or even pain (187). The effects of changes to the normal rectal fluid pH on 
the epithelial integrity, colorectal microbiota and HIV transmission are not well 
understood. Thus, it seems advisable that microbicide products maintain the pH at 
values around 7-8 since extreme values may become problematic, particularly with 
long-term use (188, 189). Some data, however, suggest that a wider pH range may 
still be safe. For instances, Good™ Clean Love (Good Clean Love, Inc.), an aqueous 
lubricant with pH around 4.8, was shown to maintain epithelial viability of Caco-2 
cells and the integrity of colorectal explants (161). Also, to date, most gels used in 
rectal clinical trials (Table 2.2) have been formulated for vaginal administration, with 
pH values around those normal for the vagina (around 4-5). In the cases of RMP-01 
and MTN-007 trials, no adverse effects or changes in epithelial integrity were 
reported up to a maximum of seven days of product use (127, 129). However, no 
systematic in vitro or in vivo testing of the safety for extended use of low pH products, 
namely on the distal GIT, has been performed so far and further work is required. 
Finally, a recent draft position paper from the World Health Organization (WHO) 
recommends that the pH for lubricants used concomitantly with condoms during 
rectal intercourse should be in the range of 5.5 to 7, with higher pH values being 
discouraged due to potential poor product preservation (190).  
 
    
2.4.2.6. Osmolality 
 
There is a growing body of evidence that osmolality can impact significantly 
the safety of rectally applied products. For instances, the adverse effects observed 
during the RMP-02/MTN-006 clinical study (7-day rectal use of 1% TFV vaginal gel) 
were associated with the hyperosmolality (3,111 mOsm/Kg) of tested formulation 
(128). These observations add up to the existing in vitro and in vivo studies using 
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commercially available lubricants, showing that hyperosmolal gels can indeed cause 
rectal epithelial damage (160, 191, 192) and potentially enhance HIV infection risk 
(193). The same behavior was observed for an hyperosmolal enema rectally 
administered (185). In particular, the high content in glycerin, a common excipient in 
rectal products, is usually responsible for these high values of osmolality. The WHO 
advises that the osmolality of lubricants (either vaginal or rectal) to be used 
concomitantly with condoms should be preferably equal or less than 1,200 mOsm/kg 
(190). Levels of glycerin, propylene glycol, or a mixture of glycols are recommended 
to be maintained at or below 9.9% (w/w), 8.3% (w/w), or around 8.3% (w/w), 
respectively, in order to achieve the previous. Results from an in vitro study showed 
that 1% TFV gels containing either 5% or 20% glycerin (836 and 3,111 mOsm/kg, 
respectively) presented different toxicity profiles (Figure 2.8) (194). Epithelial fracture 
and sloughing in polarized colorectal explants was only observed for the 20% 
glycerin formulation, while other characteristics of the vaginal formulation, namely 
rheological profile, drug release profile, tissue permeability and in vitro activity, were 
maintained (194). The 5% glycerin gel was further tested in the MTN-007 Phase 1 
clinical trial, showing to be generally tolerable and safe (129). Even so, some 
adverse events were still observed but with lower incidence and severity than those 
observed in the RMP-02/MTN-006 study (128). A recent Phase 1 study, CHARM-01, 
evaluated the impact on mucosal safety of three different formulations of 1% TFV gel 
presenting different osmolality values: the 20% glycerin original vaginal gel, and two 
5% glycerin formulations, namely the reduced glycerin gel and the rectal specific gel 
(Table 2.2) (195). All the three formulations were found safe. However, these results 
should be interpreted carefully since the safety profile of the original vaginal gel was 
ascertained based on one single exposure, while the reduced glycerin gel and rectal 
specific gel were administered for seven consecutive days. Curiously, and despite 
the osmolality of the reduced glycerin gel being half of the rectal specific gel, no 
differences were found regarding their safety profiles (131). 
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Figure 2.8. Representative tissue histology after exposure of polarized colorectal explants to 
a 20% glycerin TFV gel and a reduced glycerin (5%) tenofovir gel (RG-TFV). Colorectal 
explants were exposed overnight to 1:5 dilutions of either 5% or 20% glycerin gels, or a 2% 
N-9 gel (Gynol II, Ortho-McNeil-Janssen Pharmaceutical). Untreated explants were used as 
control. Colorectal epithelium was intact after exposure to the 5% glycerin TFV gel while the 
epithelium was fractured or sloughed off after exposure to the 20% glycerin TFV gel. 
Adapted from (194), Copyright (2012) with permission from the Oxford University Press. 
 
 
 
Even if the 1,200 mOsm/kg upper limit has been defined as acceptable, it still 
seems quite high and the WHO recognizes that osmolality values above 380 
mOsm/kg already represent a potential hazard, being near-isoosmolal products 
preferential (190). In vitro and animal in vivo data obtained by Dezzutti et al. (161) 
and Wang et al. (188) seem to provide evidence for this position. Another question 
relates with hypoosmolal products. Even if there is a lack of consistent data 
supporting either safety or not, the former study showed that one lubricant with 13 
mOsm/ kg (Slippery Stuff®, Wallace O’Farrell, Inc.) led to epithelial loss in colorectal 
explants, although this might have been induced by other factors (161). Thus, caution 
is advised in the case of hypoosmolal formulations.     
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2.4.2.7. Stability and shelf-life 
 
Like for other pharmaceutical products, stability testing and assignment of 
shelf-life are essential in order to assure efficacy and safety of a microbicide, and 
comply with regulatory requirements leading to marketing approval. Microbicides will 
probably require worldwide distribution, storing and use, namely in tropical settings 
where extreme temperatures and relative humidity are observed. Also, low and 
middle income regions may not have the necessary infrastructures to allow cold-
chain distribution. In these cases, solid dosage forms such as tablets offer the 
potential for improved stability as compared to liquids, gels and suppositories (196). 
There are no current specific orientations on stability testing for rectal microbicides, 
but a FDA draft guidance for vaginal microbicide development recommends that the 
stability profile for a product should be performed under long-term and accelerated 
storage conditions (197), as described by the same agency guidelines regarding 
stability testing (198). The scientific literature on microbicide stability studies has 
been scarce and mostly related with the development of vaginal microbicides. Still, 
studies should not only be restricted to chemical stability but also expanded to 
properties that are known to influence product performance such as viscosity, 
mechanical properties or pH, to name a few (199, 200). A shelf-life of years for 
microbicides is suggested although shorter timeframes may also be considered. 
 
 
2.4.2.8. Rectal applicators 
 
With the exception of suppositories, other rectal dosage forms require the use 
of an applicator. Such devices should be specifically designed for rectal use and 
assure comfortable administration of a suitable dose, while possibly allowing the 
reduction of leakage and adequate product distribution inside the rectum. Rectal 
microbicide clinical studies conducted so far relied on single dose, prefilled 
applicators originally intended for vaginal administration. However, acceptability has 
been suboptimal, with complaints about the applicator (often perceived as too large, 
poor appearance), unpleasant effects attributed to its use, difficulties in handling and 
inadequacy for casual transportation (102, 127, 201). Carballo-Diéguez et al. (202) 
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approached the problem and set out to develop a specific rectal microbicide delivery 
device, comparing its acceptability with that of a vaginal applicator among MSM 
(Figure 2.9). Surprisingly, the rectal-specific applicator was not superior to the 
vaginal applicator thus highlights that more research is required in order to fully 
understand what users want from an applicator. The results from the previous study 
also indicated that portability, discretion, aesthetical appeal and easy-to-open 
packaging are desirable features of a rectal applicator (202). More recently, the same 
applicators were tested in the Project Gel study and the results were similar the ones 
reported for the first study (134).  
 
 
 
 
Figure 2.9. Vaginal (top image) and rectal specific (bottom image) applicators compared in a 
acceptability study among MSM (202). Scale bars in both images are in centimeters (top 
scale in ruler) and inches (bottom scale in ruler). Adapted with permission from reference 
(202), Copyright (2014), with permission from Springer Science+Business Media. 
 
 
 
One relevant issue regarding applicators is the possibility to re-use them. Even 
if disposable prefilled applicators seem to be preferred by users, allowing the delivery 
of an accurate dose with faster and minimal product handling, multiple-use devices 
allow for price reduction (a major issue in resource-poor settings) and abbreviate 
ecological problems related with plastic disposal (203). Major setbacks of multiple-
dose applicators are portability, contamination, in-use stability and adequate cleaning 
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after usage. Further, alternative materials for both single- and multiple-use 
applicators are also desirable, particularly to allow cost reduction. For example, 
cheaper paper applicators being developed for the delivery of vaginal gels (204) may 
also be transposable to the rectal microbicide field. Moreover, the use of applicators 
may not be impulsive and immediate, and interfere with the spontaneity of a casual 
sexual encounter, which can potentially lead to poor usage. Thus, novel or inventive 
products that do not require an applicator must be explored.   
 
 
2.4.3. Characterization of rectal microbicide products   
 
Alongside the preliminary assessment of API(s) physicochemical and 
biological properties, rectal microbicide products should complete an extensive set of 
studies in order to characterize the above mentioned and other critical features (188). 
Different algorithms, recommendations and systematic approaches have been 
proposed in order to guide pre-clinical evaluation of anti-HIV microbicide products but 
most of these only address briefly microbicides for rectal use (146-148, 205-207). 
This manuscript does not aim to provide a detailed description of the vast collection 
of possible testing procedures applicable to rectal microbicides. Still, a schematic 
overview of relevant pre-clinical assays is presented in Figure 2.10. 
 Technological/physicochemical characterization techniques of a microbicide 
product are highly dependent on the dosage form used to incorporate the API(s). In 
any case, products should be characterized for the above discussed properties and 
exceptions require justification. The importance of technological/physicochemical 
parameters is unquestionable and their use in the establishment of different models 
may be useful in predicting the performance of microbicide products in the rectum. 
For example, mathematical modeling may be advantageous in studying product 
spreading and retention in vaginal and rectal compartments, particularly at 
development and optimization stages (208).  
Further, microbicide products are required to be compatible with condoms. 
Water-, glycol- and silicone-based products are usually acceptable for use with 
condoms, contrasting with oil-based formulations, although specific testing is 
required. Additional information on the subject and lubricant-condom compatibility 
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testing guidance has been published in 2010 and revised in 2013 by the WHO and 
can be readily used for microbicide development (209). Multiple testing standards 
and protocols are also available, namely from the International Organization for 
Standardization (www.iso.org) and ASTM International (www.astm.org). 
 
 
 
 
Figure  2.10. Pre-clinical testing of rectal microbicide products: 
technological/physicochemical, activity/efficacy, toxicity/safety and PK assessment. API, 
active pharmaceutical ingredient; CC50, half-maximal cytotoxicity concentration; EC50, half-
maximal effective concentration; NHP, non-human primates; PBMCs, peripheral blood 
mononuclear cells.  
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Even if API(s) have been shown effective in inhibiting the virus, formulation 
into a microbicide product may impact activity (210, 211). Products should be 
sequentially evaluated in cell, tissue and animal models for activity/efficacy and 
toxicity/safety. The presence of different ARV compounds may further lead to 
synergistic or additive effects. In vitro activity should be evaluated against both 
CCR5- and CXCR4-tropic HIV-1 (and ideally against HIV-2), cell-free and cell-
associated virus, and different lab strains and clinical isolates. Several primary cells 
or established cell lines expressing CD4 and one or both co-receptors can be used, 
although peripheral blood mononuclear cells (PBMCs) and TZM-bl cells are the most 
commonly used in initial screening. The use of CXCR4 expressing cells is usually 
limited to the compounds previously found to be active against CCR5-tropic viruses. 
The maintenance of the antiviral activity should be accessed also in the presence of 
natural and/or simulated seminal and rectal fluids and under rectal environment 
conditions. Also, colorectal explants abbreviate lack of tissue organization of most 
cell-based assays and allow better mimicking natural infection. Animal models 
susceptible to HIV (or SHIV) are reserved for late stage efficacy testing, mainly due 
to cost, handling and ethical restrictions, particularly relevant in the case of NHP 
(212). Interspecies differences at the anatomical and physiological levels require to 
be considered when formulating a product, namely when miniaturization or pH 
changes are required. In fact, these differences may impair the true value of animal 
efficacy studies as lack of translation of data obtained from animal models to humans 
has been reported, namely for humanized mice (213). 
Paralleling with antiviral activity/inhibition of transmission testing, the toxicity of 
microbicide products to cells, tissues and microbiota, as well as their ability to 
modulate pro-inflammatory responses, needs to be accessed. The combination of 
antiviral activity and cytotoxicity data allows defining the selectivity index (SI) of an 
API or product, which will be invaluable in guiding through the selection of an 
appropriate dose (or dose range) for early clinical trials. The interactions between the 
microbicide product and the rectal environment (pH, microbiota, rectal ampoule 
contents, mucus and semen) should be clearly understood in a way that assures the 
activity and safety of microbicide compounds. In the case of animal safety/toxicity 
testing, different species have been used. Although HIV-susceptible models do not 
Chapter 2 ǁ Literature Review 
50 
 
seem essential, their inclusion may be beneficial in terms of identifying events that 
lead to enhanced viral transmission. 
More recently, PK studies have been introduced into the field of microbicides 
since there is growing clinical evidence of a direct correlation between cell/tissue 
drug levels and protection (214). In vitro models, namely Caco-2 cell monolayers, 
provide a useful screening method to assess permeability and cell/tissue 
accumulation (215). However, pre-clinical rectal PK studies have been mostly 
performed in NHP (121, 122, 216, 217). Rectal tissues and rectal fluids (collected as 
lavages or by means of sponges/swabs) are used for analyzing the absorption and 
local distribution pattern of the microbicide compounds, while blood samples are 
useful in determining the extent of systemic exposure. These data and their 
correlation may be useful in the preliminary design of clinical trials, including 
statistical modeling (218). Another interesting feature in some of these PK studies is 
the evidence of a transference pattern of the drug between rectal and vaginal tissues 
following either type of administration (216, 219). Although not completely explored, 
the local metabolism of ARV drugs in colorectal tissues when administered topically 
is another issue that needs to be considered since multiple enzymes of cytochrome 
P450 and UDP-glucoronosyltransferase families are actively expressed in different 
parts of the human colon and are able to metabolize ARV drugs such as dapivirine 
and MVC (220, 221). Finally, one particularly neglected issue has been the effect of 
microbicides in insertive partners, mainly because relatively brief penile exposure is 
expected. However, clinical evidence indicates that there is the potential for 
significant local and systemic drug exposure once a microbicide gel is applied to the 
penis, which could lead, for example, to toxic effects (222). Thus, it seems advisable 
that this concern should also be considered early on pre-clinical studies. 
 
 
2.4.4. User acceptability issues  
 
Product acceptability is expected to be critical to the overall adherence and, 
ultimately, the effectiveness of rectal microbicides. The problem is simple: if not used 
consistently, microbicides cannot protect adequately from viral transmission. 
However, the concept of acceptability is not easy to study because it is strongly 
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influenced by multiple factors, including cultural and social, and depends not only on 
users but also on their partners’ preferences. Acceptability product strongly 
correlates with PK and safety, which combined may influence the overall efficacy of a 
microbicide product  (223). Early opinion in the field was not clear as to the relevance 
of acceptability studies prior to the demonstration of clinical efficacy or the usefulness 
of such findings to early pre-clinical microbicide development (224). 
However, it is currently recognized that acceptability is of paramount 
importance in assuring protection, being intimately linked to readily perceived and 
subjective characteristics of the microbicide product. Features such as consistency, 
texture, organoleptic properties (taste, odor and color), format, size/volume to be 
administered, easiness to administer, package/applicator design are determinant for 
product acceptability. The final characteristics of a rectal microbicide can influence 
performance namely various in-use effects (before, during and after intercourse), 
frequency and timing of product use, duration of protection, lubrication, use 
with/without condom, changes in hygiene practices, and side effects (169, 225). 
Other factors, including concomitant anal and vaginal sex in the same encounter, and 
preferences and attitudes of partners relating to the product are important variables 
that need to be considered. Age, gender, economical status (intimately related to 
microbicide cost) are additional aspects that significantly impact patterns of product 
acceptability or the strength of product preferences (169). These issues impair 
achieving a “one size fits all” kind of product and multiple equivalent options should 
be considered during microbicide development. Table 2.3 summarizes the findings of 
different acceptability studies regarding the rectal use of microbicide or 
placebo/lubricant products. In general, gels seem preferred over other dosage forms, 
mainly due to their acceptable organoleptic features. As discussed, volume is an 
important issue regarding performance but, contrasting with vaginal use, rectal 
administration of relatively high amounts of gels seems to be possible without 
affecting acceptability significantly. Moreover, safety, in-use feel and comfort are 
significant issues towards good acceptability. Unfortunately, it appears that a 
universal ideal product cannot be established from the acceptability point of view and 
further work in the field is required. 
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Table 2.3. Acceptability outcomes of the clinical evaluation of different rectal microbicide or 
surrogate products. 
Product Population Acceptability main findings Refs 
N-9 gel (a) MSM (n=70) 
Less than half of the participants reported intention 
to use if approved. Some problems with gel 
application reported due to (vaginal) applicator 
design. Considered too sticky and drying out too 
quickly. Unappealing taste, smell, and color. 
(102) 
FemGlide® gel 
(a) MSM (n=20) 
Up to 35 mL of gel administration was generally 
acceptable. Acceptable volume was dependent on 
sexual activity/rest. Transparent and odorless 
features were acceptable. Likelihood of future use 
was high. 
(186) 
FemGlide® gel 
(a) or PEG-based 
suppositories 
MSM (n=77) 
Gel was overall preferred over suppository, namely 
in color, smell, consistency, and feeling in rectum 
immediately after insertion and/or 30 minutes after 
insertion. 
(168) 
0.1% or 0.25% 
UC781 gel (a) 
MSM/women 
(n=36) 
Overall well acceptable. Participants reported high 
intention to use if approved. 
(127, 
201) 
TFV 1% gel (a) 
MSM/women 
(n=18) 
One quarter of participants liked the gel (likelihood 
of future use around 75%). Adverse effects reported 
(probably related with hyperosmolality). 
(128) 
Reduced-
glycerin TFV 1% 
gel 
MSM/women 
(n=65) 
Likelihood of future use was 87% vs. 93% for a 
HEC gel. 
(129) 
Enema (b), 
lubricant gel (c), 
or suppository 
(d) 
MSM/women 
(n=117) 
Gel received highest overall acceptability score. 
Younger males preferred gel but older ones did not 
show preference among tested products. 
(169) 
(a) Originally intended for vaginal administration; (b) 125 mL Normosol®-R filled in an enema bottle; (c) 4 mL 
Pre-Seed® in pre-filled vaginal applicator; (d) Tucks™ (1.4 g).   
 
 
 
2.4.5. Manufacturing, distribution and affordability 
 
Rectal microbicides should be reasonably priced (or even ideally free), 
particularly in resource-poor countries where most of the individuals at high-risk of 
infection live. The manufacturing process should comply with current good 
manufacturing practice (cGMP) and allow obtaining quality products at minimal 
prices. Formulation strategies, in particular, play a decisive role in the selection of 
suitable excipients at reduced costs and manufacturing techniques that should ideally 
be widely available, readily transposable among different sites or different scales, 
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and require inexpensive equipments. Dosage forms so far being developed as rectal 
microbicides, namely gels, are quite affordable and easily produced in large-scale 
batches. For example, the 1% TFV vaginal gel produced in the USA and used in the 
RMP-02/MTN-006 clinical trial (128) may potentially be commercially available at an 
estimated cost of US $0.13 per dose (considering a multi-use tube with a reusable 
applicator), with prices rising to near US $0.20/dose or US $0.66 when considering 
the use of paper applicators or pre-filled single-use plastic applicators, respectively 
(226). In particular, prices for the 1% TFV gel as delivered by reusable applicators or 
even single-use paper applicators may be considered reasonable in order to assure 
cost-effectiveness at resource-poor countries, depending on the degree of protection 
provided, the available support from governmental and non-governmental agencies 
involved in the fight against HIV/AIDS, and partnership with the pharmaceutical 
industry (227). Assessing users’ willingness to pay for microbicides is also important. 
For example, a recent acceptability study using conjoint analysis, i.e., considering 
different hypothetical product characteristics and measuring their value to users, 
found that prices of around US $0.30 per dose were regarded as affordable by South 
American MSM willing to use rectal microbicides (228). Moreover, further strategies 
to reduce costs are required and include, among others, the transfer of 
manufacturing to regions where labor cost is lower or are closer to distribution areas. 
Also, rational microbicide product demand and usage forecasting modeling, as well 
as the use of already relevant commercial (e.g., condoms), health systems or civil 
society organizations distribution channels may be advantageous (229). Finally, 
products potentially providing long-term protection, such as rings in the case of 
vaginal delivery, may also allow savings (cost per dose) despite higher production 
costs per unit. However, no such rectal microbicide product is currently being 
developed.      
 
 
2.4.6. Novel rectal microbicide drug delivery approaches   
 
As the field of rectal microbicides is growing, new ideas are flourishing in order 
to develop enhanced drug delivery solutions. As described above, rectal microbicides 
have been mostly developed as aqueous-based formulations, namely hydrophilic 
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gels. Despite that, non-aqueous systems may also provide interesting platforms for 
microbicide delivery. For instances, Wang et al. (188) proposed two different lipid-
based rectal placebo formulations: one liquid (isopropyl myristate, myristyl miristate) 
and one gel (glyceryl stearate and PEG-75 stearate, caprylic/capric triglyceride, 
vitamin E acetate). Both were shown non-toxic in human rectal explants and non-
irritating upon delivery in a rabbit model, thus potentially providing alternative safe 
options for rectal microbicide delivery. Further, both systems were prepared under 
cGMP and could be easily scaled-up to industrial manufacturing. 
The use nanotechnology-based drug systems is an emergent strategy for the 
delivery of microbicide drug candidates, offering several potential advantages over 
more conventional systems (230). Again, work conducted so far has mainly focused 
on vaginal microbicides but first steps have already been taken towards the 
development of nanocarrier-based rectal microbicides (231). Most data obtained so 
far concerns Vivagel® (Starpharma Pty Ltd.), a carbomer-based gel containing a 
dendrimer (SPL7013) (232). SPL7013 is not a drug nanocarrier but possesses itself 
antiviral activity due to the terminal naphthalene disulfonate groups of this fourth-
generation dendrimer. Relevant to its potential rectal use, a 5% SPL7013 gel showed 
reduced toxicity to Caco-2 cells (233), but caused epithelial shedding of colorectal 
explants despite reducing HIV-1 infection by over 85% (50). Toxicity was associated 
to the vehicle rather than the dendrimer. A 3% SPL7013 gel was also found safe 
when tested in pigtailed macaques after trice rectal application for four days (51). 
More recently, das Neves et al. (47, 234) showed that poly(ethylene oxide)-
modified poly(-caprolactone)-based NPs (PEO-PCL NPs) could be useful as a 
potential nanocarrier (200 nm) for the non-nucleoside reverse transcriptase inhibitor 
(NNRTI) drug dapivirine, namely for rectal administration. Dapivirine-loaded PEO-
PCL NPs were able to increase intracellular levels of the drug in Caco-2 cells and 
different immune cells relevant to HIV sexual transmission, while reducing the 
cytotoxicity of dapivirine in suspension. However, similar sized NPs prepared with 
different surface modifiers, namely dodecyl sulfate or cetyltrimethylammonium 
bromide, presented higher toxicity thus opposing their use (234). These observations 
were correlated with the intrinsic toxicity of these two compounds. Drug-loaded PEO-
PCL NPs also allowed increasing tissue levels in pig rectal explants while reducing 
the amount of permeating dapivirine (47). These results suggest that proposed NPs 
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may have the potential to enhance local mucosal drug levels but decrease systemic 
exposure. However, further expanded studies, including in vivo assessment, are 
required in order to fully understand the value of PEO-PCL NPs as carriers for rectal 
delivery of dapivirine. In another recent and interesting work, Samizadeh et al. (235) 
studied several in vitro and in vivo features of amprenavir-PEG-Bac7 nano-
conjugates (no size reported) in order to attest their potential as a microbicide for 
preventing rectal HIV transmission. The incorporation of the cell penetrating peptide 
(CPP) Bac7, as well as the adequate selection of the MW of PEG, were shown 
essential in allowing maintenance of the native antiretroviral activity of the ARV drug 
amprenavir. The full nano-conjugate was not tested in vivo but preliminary data for 
fluorescent labeled amprenavir-PEG3.4kDa-FITC and Bac7-PEG3.4kDa-FITC surrogates 
suggested that prolonged colorectal retention was possible due to the presence of 
the CPP. However, more studies with the actual drug nano-conjugate are required in 
order to fully assess the potential of the system (235).     
 Another conceptual approach is that of orally-delivered microbicides. This 
strategy differs from oral pre-exposure prophylaxis (PrEP) in that products are 
intended to release API(s) in the vicinities of the colorectum in order to allow topical 
action and minimize systemic absorption. Despite evident technical and physiological 
challenges, colorectal drug delivery is a well-developed topic and different 
approaches towards the problem have been proposed (236). This strategy might help 
circumvent acceptability and adherence issues but, at the same time, its 
implementation would require long-term use since rapid onset of protection would not 
be possible with discontinuous use. In an exploratory study, Li et al. (237) described 
commensal bacteria that were genetically-modified in order to secrete cyanovirin-N. 
After incorporation in yogurt and fed to pigtail macaques, these bacteria were able to 
deliver cyanovirin-N to the rectal cavity and reduce viral peak levels in rectal biopsies 
challenged ex vivo with SHIV. However, complete inhibition of viral replication was 
not achieved, thus suggesting that additional measures (e.g., bacteria secreting 
multiple antiviral agents, refinement of the delivery vehicle) are required. In another 
report, Zhu et al. (238) developed poly(lactide-co-glycolide) NPs, loaded with a 
peptide antigen and toll-like receptor ligands, incorporated in pH-sensitive 
microparticles based on polymethacrylate copolymers for the induction of colorectal 
immunity. The NP-in-microparticle system was orally delivered to BALB/c mice and 
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shown equally effective as the vaccine delivered by the colorectal route in protecting 
animals from colorectal challenge with vaccinia virus. Again, this study seems to 
backup the possibility of an oral-delivered, rectal-targeted microbicide approach.  
 
 
2.5. Conclusions 
 
 Despite great advances, the development of rectal microbicides is still in its 
infancy. Formulation and product design aspects, as well as acceptability issues, are 
attracting increased interest in the field of HIV prevention due to their tremendous 
impact on the potential success (or failure) of microbicides. After several years 
following on the footsteps of vaginal counterparts, rectal microbicides are gaining 
momentum but concise guiding for the development of such products is still missing. 
Despite that, current opinion favors formulating specific rectal microbicides in view of 
the present knowledge on the mechanisms of rectal HIV infection and product 
interactions with the rectal environment (mucus, content, microbiota, among others). 
Still, some questions related with the ideal volume required to provide complete 
protection, suitability of the gels and other dosage forms to incorporate and properly 
deliver novel microbicide candidates, product distribution and retention along 
mucosal surfaces and at target sites, and user preferences for specific dosage forms 
remain to be answer. Overall, one rectal microbicide product may not fit all and the 
development of various equivalent products may be an interesting approach. Also, 
dual compartment products are tempting and are being actively explored, but their 
feasibility still needs to be clearly demonstrated. Finally, recent trend towards the 
development of next-generation combination microbicides is an important aspect of 
the field, which poses substantial challenges to formulation scientists. Presently, a 
standard safe, effective and highly acceptable rectal microbicide still seems elusive 
but, as explored in this work, may be achievable. Innovative drug delivery 
approaches and novel strategies are also now emerging and, by their own or allied to 
conventional dosage forms, may provide highly sophisticated delivery solutions for 
rectal microbicides.   
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3.1. Abstract 
 
 Dense surface modification with short chain polyethylene glycol (PEG) has 
been previously demonstrated as favoring the transport of nanoparticles (NPs) 
across mucus. However, the ability of such approach to influence the distribution and 
retention of NPs along the length of the colorectum after rectal delivery has not been 
previously established. Herein, the distribution and retention of poly(lactic-co-glycolic 
acid) (PLGA) NPs modified with PEG in a non-covalent fashion are reckoned in a 
mouse model. Despite overall rapid depletion, both PEG-modified and non-modified 
NPs are able to reach the middle segment of the colon. PEG-modified NPs are able 
to enhance retention up to at least two hours post-administration, contrasting with 
nearly residual levels observed for non-modified NPs after 15 minutes. The ability of 
PEG-modified NPs to putatively cross mucus also appears to promote association 
with tissues. Overall, the work provides significant insights as to the behavior of NPs 
in the colorectum, which could be valuable for the development of rectal 
nanomedicines. It further reinforces the potential usefulness of PEG-modified NPs as 
mucus-penetrating carriers for mucosal drug delivery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 ǁ PEG modification enhances colorectal distribution and retention of NPs 
 
82 
 
3.2. Introduction  
  
 Rectal administration of drugs is a long and well-established medical practice. 
Its value has been demonstrated for both the management of local conditions (e.g., 
inflammatory bowel disease (1), irritable bowel syndrome (2) or constipation(3)), and 
systemic diseases, particularly in children and the elderly (4, 5). Also, in recent years, 
advances in rectal drug delivery have been mostly set by efforts in developing anti-
HIV microbicides (6). The rectal route typically provides the possibility to increase 
drug levels at mucosal fluids and tissues that could not be otherwise safely obtained 
by oral or intravenous administration. Various products for rectal use are available in 
the form of enemas, suppositories, foams or semisolid systems (e.g., gels). However, 
conventional dosage forms frequently display disadvantageous features such as poor 
colorectal distribution and/or retention, thus leading to sub-optimal PK (7). 
Nanotechnology-based drug delivery systems may help circumventing these 
problems depending on adequate engineering. One particular aspect determining the 
fate of drug carriers is that of the interaction with mucus. Despite commonly 
considered as beneficial, mucoadhesive properties of nanosystems lead to their 
reduced ability to be transported in mucus and cross this barrier towards the mucosal 
surface (8). The development of mucus penetrating NPs by densely modifying the 
surface of otherwise mucoadhesive systems with linear, low MW PEG has been a 
major breakthrough in order to potentially promote distribution and retention at 
mucosal sites (9-11). PEG provides an inert surface layer that allows abbreviating the 
establishment of adhesive interactions with mucin chains. In particular, extensive in 
vivo data support that PEG-modified NPs enhance coating of the vaginal mucosa by 
NPs while increasing retention in loco (12-15). Similar behavior has been described 
for NPs at both the lower and upper intestinal tract; distribution of mucoadhesive 
systems was generally restricted to the jejunal/colorectal lumen whereas mucus 
penetrating NPs featured improved coating of epithelial surfaces (16, 17). 
However, several questions regarding the advantages of mucus penetrating 
NPs remain unclear. For instance, most in vivo studies so far conducted have only 
presented results regarding qualitative distribution of NPs across discrete sections of 
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mucosae, highlighting lumen-epithelial transport. Moreover, no data are available 
regarding their time-dependent and longitudinal distribution (i.e., along the full 
extension of the colon) as compared to mucoadhesive counterparts upon 
administration in the rectum. Understanding the distribution and retention dynamics 
of NPs throughout the different parts of the colorectum over time, both qualitatively 
and quantitatively, may further support the value of nanotechnology-based carriers 
for rectal administration of drugs. Moreover, such information may help settling the 
ongoing debate on whether mucus penetrating NPs may provide or not significant 
advantage over mucoadhesive ones, in particular for the rectal route (18). 
Herein, we produced and extensively characterized putative mucus 
penetrating PLGA NPs by densely modifying their surface with PEG of approximately 
5 kDa in a non-covalent way using poloxamer 407, a triblock copolymer of PEG- 
PPG-PEG. These NPs were then tested in a mouse model for quantitative 
distribution throughout the length of the colorectum after rectal administration. 
Generated data indicated that mucus penetrating NPs performed better than non-
modified mucoadhesive counterparts in terms of in vivo distribution and retention. 
 
 
3.3. Materials and Methods 
 
3.3.1. Materials and animals 
 
 End-capped PLGA with 50:50 D,L-lactide:glycolide ratio and 0.2 dL g1 
inherent viscosity (Purasorb PDLG 5004) was a kind offer from Corbion (Gorinchem, 
The Netherlands). Poloxamer 407 (Kolliphor® P 407) was purchased from BASF 
(Ludwigshafen, Germany), Coumarin-6 (C6) from Sigma-Aldrich (Schnelldorf, 
Germany) and Cyanine7.5 carboxylic acid (Cy7.5) from Lumiprobe (Hannover, 
Germany). All other materials and reagents were of analytical grade or equivalent. 
Male CD-1 IGS mice were acquired from Harlan (Barcelona, Spain). All experiments 
were approved by the Ethics Committee at Instituto Universitário de Ciências da 
Saúde (process no. 01/ORBEACESPU/2014) and conducted at CESPU and i3S 
animal facilities under FELASA and the European Directive 2010/63/EU guidance. 
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3.3.2. Production of nanoparticles 
 
 PLGA NPs were produced by a nanoprecipitation method (19). Twenty 
milligrams of polymer were dissolved in acetone (1 mL) and slowly injected using a 
23G needle into a poloxamer 407 aqueous solution (0.1% w/v) under magnetic 
stirring (Figure 3.1). NPs were collected after 3 h under stirring at room temperature, 
washed twice with 10 mL of ultrapure water using a 100 kDa MWCO filter system 
(Amicon® Ultra-15 filter, Tullagreen, Ireland) and concentrated to 20 mg mL1. 
Particles (20 mg) were modified with PEG by incubation into 9 mL of poloxamer 407 
aqueous solutions of different concentrations (0% to 4% w/v) for 12 h. Plain PLGA 
NPs (incubated in water without poloxamer 407) and PEG-modified counterparts 
(PEG-PLGA NPs) were again concentrated to 20 mg mL1 using Amicon® filters. 
NPs were freeze-dried whenever required. Fluorescent PLGA NPs and PEG-PLGA 
NPs were obtained using the same methodology but co-dissolving either 0.8 mg of 
C6 or 4 g of Cy7.5 with PLGA in acetone. The fluorescent signal intensity of PLGA 
NPs and PEG-PLGA NPs was equivalent for each probe.  
 
 
 
 
 
Figure 3.1. Schematic representation of the used nanoprecipitation technique. 
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3.3.3. Characterization of nanoparticles 
 
 NPs were characterized for hydrodynamic diameter and polydispersity index 
(PdI) by dynamic light scattering (DLS), and zeta potential (ZP) by laser Doppler 
anemometry (LDA) after dispersion at a concentration of 0.2 mg mL1 in 10 mM 
sodium chloride solution (pH 7.0) using a Zetasizer Nano ZS (Malvern, 
Worcestershire, UK) at 25˚C. Surface morphology and size confirmation of NPs was 
performed by transmission electron microscopy (TEM) using a JEM-1400 microscope 
(JEOL, Tokyo, Japan) at an acceleration voltage of 80 kV. Ten microliters of the 
dispersion of NPs (20 mg mL1) were placed on a grid and treated with uranyl acetate 
before imaging. Energy dispersive spectroscopy (EDS) elementary analysis was 
performed by mounting samples of NPs on nickel grids and a beryllium holder (EM-
21150, JEOL) and using an X-Max 80 mm2 (Oxford Instruments, Bucks, England) 
operated at 80 kV coupled to the TEM. Chemical characterization of the surface of 
freeze-dried NPs was further conducted by proton nuclear magnetic resonance (1H 
NMR) using a Bruker Avance III 400 Novo (Billerica, MA, United States). Spectra of 
NPs dissolved in dimethyl sulfoxide-d6 (DMSO-d6) were obtained at room 
temperature, 400 MHz, 10 s relaxation time, and 90˚ pulse. Briefly, a known amount 
of PEG-PLGA NPs, PLGA NPs and poloxamer 407 was weighted and dissolved in 
DMSO-d6. Quantification of PEG was performed by integration of corresponding peak 
areas. Contact angle measurements of NP-coated surfaces were conducted by using 
the sessile drop method in an OCA 15 measuring device (DataPhysics, Filderstadt, 
Germany) equipped with a CCD video camera and SCA 20 software as previously 
described (20). Briefly, gold-coated silicon wafers (INESC-MN, Lisbon, Portugal) 
were homogenously covered with approximately 50 L of aqueous suspensions of 
NPs (20 mg mL1) and left to dry overnight at room temperature under normal 
pressure, followed by 1 h under vacuum. Surface images taken at 2 s intervals over a 
total of 200 s were used to determine the droplet profiles of 4 μL of ultrapure water. 
Profiles were fitted using the ellipse method and water contact angle values were 
calculated by extrapolating the time-dependent curve to zero. The stability of PEG 
coating was determined by placing NPs suspended in water (0.5 mg mL1) at 37˚C  
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under 100 rpm magnetic stirring. Samples were collected over 120 h, diluted to 0.2 
mg mL1 with sodium chloride solution (final concentration of 10 mM, pH 7.0), and the 
ZP measured by LDA. 
 
 
3.3.4. In vivo studies 
 
 Mice (7-12 week old) were fasted for 24 h with free access to water before 
experiments. The rectum was also gently flushed with 200 µL of water using a plastic 
pipette tip, 30 min prior to the administration of NPs. Fresh fluorescent (C6- or Cy7.5-
loaded) PLGA NPs or PEG-PLGA NPs (0.9 mg) were dispersed in 20 µL of PBS, pH 
7.4 and administered with the aid of a plastic pipette tip inserted in the colorectum to 
a depth of approximately 0.5 cm. Mice were restrained in a head-down position for 
approximately two minutes in order to minimize leakage before returning to individual 
cages under unrestrained conditions and re-allowed access to food and water. Whole 
body near infrared (NIR) imaging of animals treated with Cy7.5-loaded NPs was 
performed at pre-established time points by using an IVIS Lumina LT system (Perkin 
Elmer, Waltham, MA, USA) after brief anesthetization with inhalational isoflurane. 
Abdominal fur was removed with a hair clipper before imaging. Background signal 
from non-treated animals was used to establish relevant radiance signal ( 0.4108 p 
cm2 s1 W1). 
Animals were sacrificed at 15 min, 2 h or 6 h by isoflurane overdose followed 
by cervical dislocation. Necropsy was then performed and the terminal fraction of the 
GIT isolated. In the case of animals administered with Cy7.5-loaded NPs, tissues 
were placed in petri dishes and analyzed using the IVIS system. Background signal 
from the terminal GIT of non-treated animals was used to establish the relevant 
radiance signal ( 0.6108 p cm2 s1 W1). Quantification of the radiant efficiency 
from same sized regions including complete excised tissues was performed using 
Living Image® software v. 4.4 (Caliper, Hopkinton, MA, USA). Grey-scale 
photographs superimposed with radiance signal maps were used to manually 
determine the maximum distance covered by NPs, expressed as the maximum 
percentage of the full length of the colorectum, with the aid of the segmented line tool 
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from ImageJ software (v. 1.51j8, NIH, Rockville, MD, USA). As for mice treated with 
C6-loaded NPs, the terminal part of the GIT was divided into three equal sized 
segments: distal (included the rectum and anus), middle and proximal. Cecum and 
the terminal portion of the ileum (roughly 2 cm) were also collected for analysis. The 
central portion of each segment (corresponding to approximately 5 mm) was 
collected, frozen at 80 ˚C in O.C.T. Compound (Thermo Scientific, Runcorn, UK) 
and processed for fluorescence imaging. Briefly, 7 m transversal cryosections were 
stained by DAPI (4',6-diamidino-2-phenylindole dihydrochloride) (Sigma-Aldrich) and 
CellMask™ Orange Plasma membrane Stain (Thermo Scientific), and mounted using 
Vectashield® (Vector Laboratories, Burlingame, CA, USA). Images were obtained 
using an Axiovert 200M inverted fluorescent microscope (Carl Zeiss, Göttingen, 
Germany). In the case of quantitative analysis, each colon segment was flushed with 
PBS (550 µL) and collected fluids, as well as tissues, were stored at 80 ˚C until 
further processing. After thawing, washing fluids and tissues were mixed with 
acetonitrile, homogenized either by using a vortex for fluids or an Ultra-Turrax 
processor (IKA®-Werke, Staufen, Germany) for tissues, resulting homogenates 
centrifuged at 13,414 ×g for 10 min at 4˚C, and the supernatants collect and used for 
assaying at 460/540 nm. C6 standards were similarly prepared and used for 
generating calibration curves. The method was linear over the range of 0.02-5 µg 
mL1 (R2  0.9987), with detection and quantification limits of 0.01 µg mL1 and 0.02 
µg mL1, respectively, as assessed based on the standard deviation (SD) of the 
response and the slope (21). C6 fluorescence quantification in samples was 
conducted by using a Synergy™ Mx microplate reader (BioTek Instruments, 
Winooski, VT, USA). 
 
 
3.3.5. Statistical analysis 
 
 Analysis was performed using Student’s t-test (two group comparisons) or 
one-way ANOVA with post-hoc Tukey's HSD test (multiple comparisons). All data 
were processed using Prism 5.01 software (GraphPad Software, La Jolla, CA, USA) 
and p < 0.05 was accepted as denoting significance. 
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3.4. Results and Discussion 
 
3.4.1. Production and characterization of nanoparticles 
 
 We successfully produced PLGA NPs by adapting a previously established 
method (19). NPs featured mean values for hydrodynamic diameter, PdI and ZP of 
221 ± 1 nm, 0.066 ± 0.022 and 6.6 ± 0.2 mV, respectively. Further, non-covalent 
coating of NPs with PEG (PEG-PLGA NPs) was pursued by incubation with a 
poloxamer 407 solution in order to allow surface adsorption. The molecular mass 
ratio of PEG (4.5103 g mol1) and PPG (3.3103 g mol1) in the selected triblock 
copolymer has been previously shown ideal to provide dense surface coverage of 
NPs and enable mucus diffusive properties (10). Increasing concentrations of the 
poloxamer 407 solution were first tested in order to optimize the best conditions for 
PEG modification. Colloidal features of NPs did not change significantly when 
incubated in up to 4% (w/v) poloxamer 407, as compared to PLGA NPs, except for 
ZP (Fig. 3.2). Non-coated NPs presented mildly negative ZP values around 7 mV, 
while near neutral ZP was observed for PEG-modified NPs. Increasing poloxamer 
407 concentrations starting at 0.5% (w/v) did not modify significantly ZP, although a 
trend for increasing values was still apparent between 0.5% and 1%. This last 
concentration was thus selected for further studies in order to potentially assure 
dense PEG coating of the surface of NPs (22). Higher concentrations of poloxamer 
407 were not considered, as saturation of PEG at NP surface appears to be achieved 
(Fig. 3.2). The physicochemical characteristics of the final nanosystems are 
presented in Table 3.1.  
PLGA NPs and PEG-PLGA NPs were also characterized by TEM, which 
confirmed size values obtained by DLS measurements of typically round shaped and 
smooth surfaced particles (Fig.3.3).  Importantly, auxiliary experiments comprising 
EDS, 1H NMR and contact angle analysis further confirmed the presence of PEG at 
the surface of PEG-PLGA NPs as compared to PLGA NPs. In particular, increased 
carbon and decreased oxygen contents obtained for PEG-PLGA NPs as compared 
to non-modified particles in EDS analysis suggests the higher content in PEG 
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[H(OCH2CH2)nOH] and shielding of the PLGA core [(C3H4O2)x(C2H2O2)y] (23) (Table 
3.2).  
 
 
 
 
 
Figure 3.2. Colloidal features of NPs. Changes in (A) hydrodynamic diameter, (B) 
polydispersity index (PdI) and (C) zeta potential (ZP) values of PLGA NPs incubated with 
increasing concentrations of poloxamer 407. Results are presented as mean ± SD (n=3). (*) 
denotes a significant difference (p < 0.05) from NPs produced without incubation with 
poloxamer 407 (0.0%). (D) Graphical depiction of increasing NP surface density and 
saturation of PEG coating. 
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Table 3.1. Physicochemical features of PLGA and PEG-PLGA NPs. Hydrodynamic diameter 
(HD), polydispersity index (PdI), zeta potential (ZP), association efficiency (AE) and drug 
loading (DL) of empty and C6-loaded PLGA and PEG-PLGA NPs. Results are presented as 
mean ± SD (n=3). 
Nanosystem Payload HD (nm) PdI ZP (mV) 
 
AE (%) DL (%) 
PLGA NPs -- 221 ± 1 0.066 ± 0.022 -6.6 ± 0.6 --  
 C6 190 ± 3  0.332 ± 0.078 -13.1 ± 1.1  99.9 ± 0.0 3.8 ± 0.0 
PEG-PLGA 
NPs 
-- 218 ± 4 0.078 ± 0.016 -1.9 ± 0.1 --  
 C6 191 ± 6  0.173 ± 0.058 -3.8 ± 1.6 99.8 ± 0.1 3.8± 0.0 
 
 
 
Table 3.2. Energy dispersive spectroscopy results of NPs. Results denote the presence of 
carbon and oxygen at the surface of PLGA NPs and PEG-PLGA NPs. Results are presented 
as mean ± SD (n=3). 
 
 
 
 
 
 
 
 
 1H NMR analysis corroborated the results obtained by LDA and EDS analysis 
regarding the surface coating of NPs surface with poloxamer 407. Representative 1H 
NMR spectra of PLGA NPs, PEG-PLGA NPs and poloxamer 407 are presented in 
Figure 3.4. All spectra data were calibrated through the solvent peak at 2.5 ppm and 
all of them showed a characteristic peak at 3.3 ppm attributed to the presence of 
water (24). Both types of NPs presented typical peaks of PLGA at 1.47, 4.8 and 5.2 
ppm that are related with the presence of CH3, CH2, and CH protons, respectively 
(25). Appearance of peaks at 1.04 ppm (CH3) and between 3.4 and 3.6 ppm 
Samples % C % O 
PLGA NPs 93.7 ± 0.3 5.6 ± 0.2 
PEG-PLGA NPs 97.5 ± 0.1 2.5 ± 0.1 
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(attributed to CH and CH2) suggested the presence of poloxamer 407 (26). In the 
case of PLGA NPs, the presence of poloxamer 407 was residual and resulted from 
the use of this polymer as stabilizer during the production of NPs. Integration and 
normalization – required due to different MW and monomer repetition – of typical 
peaks of poloxamer 407 (1.04 ppm) and PLGA (1.47 ppm), showed a shift in 
PLGA:poloxamer 407 ratio from around 8 to 3, thus suggesting surface modification 
of NPs with PEG. 
 
 
 
Figure 3.3. Transmission electron microscopy analysis of NPs. Representative images of (A) 
PLGA NPs and (B) PEG-PLGA NPs. Both type of NPs presented round shape and smooth 
surface. Results are in agreement with data obtained by dynamic light scattering (DLS) 
measurements regarding diameter and size distribution. 
 
 
 
Further, contact angle measurements were performed in order to assess the 
hydrophobicity-hydrophilicity profile of both types of NPs.  Contact angle value of 
PEG-PLGA NPs decreased around 10˚ compared to contact angle value of PLGA 
NPs (53.3˚ Vs 62.0˚), corroborating the higher hydrophilicity of PEG-PLGA NPs, 
consistent with the presence of hydrophilic PEG chains at NPs surface (27) (Figure 
3.5).        
Despite their non-covalent nature, PEG adsorption to NPs was also shown 
persistent for at least 24 h when submitted to an in vitro washing protocol (Fig. 3.6). 
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Values for ZP were kept relatively constant within the range of 2 to 3 mV up to 24 
h. A slight but significant decrease was observed only at 72 h and 120 h. These 
results are in line with previous work that evidenced strong and stable adsorption of 
poloxamer 407 to PLGA NPs for at least 24 h (10). Taken together, these data 
support the prolonged and dense non-covalent coating of PLGA NPs with PEG, and 
substantiate their ability to be used as mucus penetrating NPs for subsequent in vivo 
studies (10). 
 
 
 
 
Figure 3.4. 1H NMR analysis of NPs. Representative spectra of PLGA NPs, PEG-PLGA NPs 
and Poloxamer were obtained in DMSO-d6 at 400 MHz (calibration performed with the 
solvent peak at 2.5 ppm).  
 
 
 
C6 was further incorporated into NPs in order to render fluorescent signal. 
Colloidal features of both C6-loaded PLGA NPs and C6-loaded PEG-PLGA NPs 
were similar to non-fluorescent counterparts (Table 3.1). Moreover, the release of C6 
from NPs was low under in vitro conditions (less than 9% in PBS, pH 7.4 at 24 h) 
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thus assuring general co-localization of C6 fluorescent signal and NPs during animal 
studies (Figure 3.7). 
 
 
Figure 3.5. Contact angle values of NPs. Water optical contact angle measurements of gold 
surfaces coated with PLGA NPs or PEG-PLGA NPs. Data analysis sustains a significant 
decrease in contact angle from mean 62.0 to 53.3 degrees when NPs were modified with 
poloxamer 407, which is consistent with the presence of hydrophilic PEG chains at the 
surface of NPs (28). Results are expressed as mean ± SD (n=3). (*) denotes a significant 
difference (p < 0.05). 
 
 
Fig. 3.6. Persistence of PEG coating of NPs. Data represents changes in (A) hydrodynamic 
diameter, (B) polydispersity index (PdI) and (C) zeta potential (ZP) of PEG-PLGA NPs over 
120 h when in water (37 ˚C, 100 rpm magnetic stirring). No changes in size and size 
distribution were apparent throughout the experiments. Results are presented as mean ± SD 
(n=3), except for 120 h (n=2). (*) denote statistically significant differences (p < 0.05) from 
NPs at time zero. 
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Figure 3.7. In vitro release profile of C6 from PLGA and PEG-PLGA NPs. Release of C6 was 
assessed over 24 hours in PBS pH 7.4 under sink conditions. Each point represents the 
mean values and bars the SD (n=3).  
 
 
 
3.4.2. In vivo distribution and retention of nanoparticles 
 
 We then proceeded with in vivo studies concerning the distribution of 
fluorescent NPs using a murine model. Male CD-1 IGS mice were fasted for 24 h and 
had their distal colon/rectum washed with water before the administration of NPs in 
order to soften and minimize fecal content and output, thus better resembling the 
human colorectal content (16). Animals were further allowed to rest for 30-40 min in 
order to replenish the normal mucus layer (29). Fluorescent PLGA NPs or PEG-
PLGA NPs (0.9 mg) were suspended in PBS and instilled intrarectally. Animals were 
conscious throughout all procedures and left unrestrained until being euthanized at 
pre-determined time points (15 min, 2 h and 6 h). We began by observing the 
behavior of PLGA NPs or PEG-PLGA NPs in different segments of the colon 
(proximal, middle and distal) regarding transport from the lumen towards the 
epithelium. Fluorescent microscopy of excised colon (Fig. 3.8) confirmed previous 
studies reporting that PEG-PLGA NPs are able to migrate across mucus and provide 
extensive coating of the intestinal epithelium (16, 17, 30). As for PLGA NPs, 
localization was mostly restricted to the lumen and only apparent at the shortest time 
point tested. This typical behavior was only observed in the middle and distal 
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segments of the colon for both types of NPs, since only residual fluorescence 
signaling was detected at the upper part of the colon. Moreover, at 2 h post-
administration, the presence of PEG-PLGA NPs at middle and distal segments was 
still evident but not in the case of PLGA NPs. Fading of most of the C6 fluorescent 
signal down to residual levels was clear at 6 h post-administration for both types of 
NPs. Interestingly, epithelial tissue penetration of mucus diffusive NPs was 
distinctively noted, particularly at 2 h after administration (Fig. 3.8). Overall, these 
data seem to indicate that PEG-modification may enhance not only the distribution of 
NPs throughout the colorectal mucosa but also prolong their residence time, as 
inferred from previous work by Maisel et al. (16, 30). 
 
 
Fig. 3.8. Distribution of NPs in the colon. Representative fluorescent microscopy images of 
transversal sections in different segments of the colon at 15 min (left panels) and 2 h (right 
panels) after rectal administration of fluorescent C6-loaded PLGA NPs and C6-loaded PEG-
PLGA NPs (see embedded captions for details). Green, blue and red signals are from C6 
(associated to NPs), DAPI (DNA) and CellMask™ Orange Plasma membrane Stain (cell 
membrane), respectively. White arrows highlight NPs embedded into tissue. 
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In order to better understand the trafficking of both types of NPs along the full 
length of the colorectum, we conducted studies regarding the quantification of C6 
fluorescent signal recovered from different sections of the lower end of the GIT. The 
terminal part of the ileum, the cecum and colorectum were collected, and individual 
lavages and tissue homogenates were obtained and processed for fluorescence 
assessment, as detailed in the experimental section. Distribution of NPs was 
restricted to the colorectum since no C6 fluorescence signal was observed at the 
cecum and ileum. Strikingly, the major fraction of administered NPs (above 85%) was 
lost within 15 min of instillation (Fig. 3.9, A). This is most certainly associated with the 
continuous, intense and unavoidable colonic propulsion and fecal output, typical of 
mice (31). Although we tried to minimize defecation before administering NPs, fasting 
and colorectal washing were only partially effective. Adding to the previous, natural 
turnover and clearance of mucus is likely to also be implicated to some extent in the 
rapid depletion of NPs (29). Observable leakage and self-grooming, although 
possible, have not been noted upon inspection throughout the duration of the study 
and necropsy. Since no previous quantitative studies regarding the retention of NPs 
following rectal administration have been conducted, it is not possible to have a 
comparative assessment of the apparently fast depletion of NPs. However, 
presented results are in line with those for NPs (180-270 nm) after vaginal 
administration to female mice (32, 33). 
PEG-PLGA NPs presented overall higher retention in the colorectum as 
compared to non-modified NPs (Fig. 3.9). Differences were only observed at earlier 
time points with mean 5.5- and 10.5-fold higher amounts of PEG-PLGA NPs at 15 
min and 2 h, respectively, as compared to PLGA NPs. No apparent differences were 
observed at 6 h post-administration. Interestingly, scanty levels at this last point 
seem to have been reached within a few minutes for PLGA NPs, while relatively 
stable amounts of PEG-PLGA NPs were achieved after initial clearance and 
maintained up to at least 2 h. An overall similar trend was observed when 
considering particles recovered only from the colorectal lumen (lavages) or tissues, 
as shown in Fig. 3.9, B-C. Significant differences were observed at 15 min for tissues 
and at 2 h for lavages. Although not reaching statistical significance, mean recovery 
of NPs at 15 min for lavages and 2 h for tissues was also in the order of 4.6- and 
15.6-fold higher, respectively, for PEG-PLGA NPs over PLGA NPs.  
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Fig. 3.9. Quantitative distribution of NPs in the colorectum. Recovery of fluorescent C6-
loaded PEG-PLGA NPs and C6-loaded PLGA NPs from (A) the whole colorectum (tissues 
and fluids), or only (B) fluids and (C) tissues at 15 min, 2 h and 6 h following administration. 
Results are expressed as the percentage of the initial amount of NPs. Columns represent 
mean values and bars the SD (n=3). (*) denotes a significant difference (p < 0.05). 
 
 
 
These results confirm previous qualitative studies and suggest that PEG-modification 
has indeed a decisive impact not only in colorectal retention but also in enhancing 
tissue uptake. Rapid transport across mucus, particularly at the outermost loosely 
adherent layers experiencing fast clearance (34), may help decreasing particle 
depletion and promote interactions and tissue penetration at the mucosa. The 
enhanced retention and tissue penetration of PEG-PLGA NPs may be of interest for 
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improving both systemic and local PK, particularly when relevant drug targets are 
present at the mucosal tissue (e.g., immune cells involved in inflammatory bowel 
disease pathogenesis (35) or in HIV transmission (36)). 
We then proceeded with the analysis of different parts of the colorectum in 
order to better understand NP distribution throughout this anatomical site following 
rectal instillation. Three equally sized proximal, middle and distal (including the 
rectum) segments were considered as schematized in Fig. 3.10, A. Again, the 
presence of both types of NPs was only apparent at the last two thirds of the 
colorectum, while only residual C6 fluorescent signal was recovered from the 
proximal segment (Fig. 3.10, B-C). Although a precise boundary for distribution could 
not be assessed, it was clear that NPs could undergo extensive retrograde migration 
(i.e., against the digestion flow) and reach locations in the colon that distanced 
several centimeters from the administration site within as little as 15 min. Although 
the administration of NPs was conducted using a liquid vehicle (20 L), this was 
performed in a gentle manner that was unlikely to promote relevant distribution 
towards the proximal end of the colon.  
Curiously, recovery of PEG-PLGA NPs at the distal segment was considerably 
higher at 2 h as compared to 15 min post-administration, both for lavages and 
tissues. We hypothesize that, following administration, rapid and intense clearance of 
NPs at the distal colon/rectum occurred, both to the exterior of the body and, in a 
retrograde way, towards the middle colon. This may be related to the intense 
propulsion and trafficking of stiffer fecal pellets at the lower part of the colon, as well 
as to voluntary defecation movements induced by the presence of fluid at the rectum 
(37-39). Mucus at the distal segment is also thicker, less permeable to particles and 
undergoes faster clearance (40, 41), which could further oppose local residence 
upon administration. Scanty levels of PEG-PLGA NPs observed after 15 min 
increased up to 2 h, presumably due to the transport of particles that have previously 
been distributed into the middle segment but are then removed alongside the natural 
digestion flow. Results for the middle colon also seem to backup this possibility since 
a decreasing trend was observed starting immediately at 15 min, at which time point 
maximal amounts of PEG-PLGA NPs were recovered. A similar behavior was not 
apparent for PLGA NPs, although the constant low levels of fluorescent signal 
recovered from the distal colon/rectum would likely impair its observation. 
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Fig. 3.10. Quantitative distribution of NPs in different segments of the colorectum. (A) 
Schematic representation of the mouse colon and delimitation of segments considered for 
distribution. Recovery of fluorescent C6-loaded PEG-PLGA NPs and C6-loaded PLGA NPs 
from fluids and tissues in the (B) distal and (C) middle sections of the colon at 15 min, 2 h 
and 6 h following administration. Results are expressed as the percentage of the initial 
amount of NPs. Columns represent mean values and bars the SD (n=3). (*) denotes a 
significant difference (p < 0.05). 
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3.4.3. Near infrared imaging of live animals and excised colorectum 
 
 To gain more insight into the distribution and retention patterns of different 
NPs in the colorectum, we proceeded with in vivo imaging experiments. For this last 
purpose, NPs emitting in the NIR were prepared by incorporating Cy7.5 (788/808 
nm) rather than C6 in order to minimize tissue scattering and absorbance. Changes 
in colloidal properties were minimal. Cy7.5-loaded PLGA NPs featured mean 
hydrodynamic diameter of 210 ± 1 nm, PdI of 0.133 ± 0.015 and ZP of 4.0 ± 0.2 mV, 
while Cy7.5-loaded PEG-PLGA NPs presented mean hydrodynamic diameter of 218 
± 2 nm, PdI of 0.115 ± 0.009 and ZP of 2.0 ± 0.1 mV. Whole body imaging of mice 
confirmed fast and extensive leakage after administration of both PLGA NPs and 
PEG-PLGA NPs, as revealed by the intense fluorescent signal at the perineal region 
(Fig. 3.11). Moreover, mild fluorescence was observed up to 15 min (PLGA NPs) or 
1 h (PEG-PLGA NPs) in the abdominal region, suggesting that PEG-modified NPs 
were able to better retain in the colon (Fig. 3.11). Low signal intensity and poor 
spatial resolution of whole body images were attributed to limited tissue penetration 
of light and natural folding of the colon that may lead to the presence of NPs at 
different abdominal depth (42).  
 
 
Fig. 3.11. Representative full body imaging of mice after rectal instillation of either Cy7.5-
loaded PLGA NPs or Cy7.5-loaded PEG-PLGA NPs. Images were taken at 5 min, 15 min, 1h 
and 2 h following administration. Heat map scale ranges from 0.4108 to 3.0108 p cm2 s1 
W1 
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In order to better estimate the transport and distribution of NPs, colorectal 
tissues of mice were isolated and analyzed for fluorescence (Fig. 3.12, A). Images 
evidenced that PEG-PLGA NPs were able to migrate farther into the colorectal tract 
than non-modified NPs.  Fluorescent signal was also more intense near the interface 
between the distal and middle colon at 15 min, thus reinforcing that clearance of 
PEG-PLGA NPs from the distal segment occurred rapidly following administration, 
both upwards into the GIT or to the outer body. Complete fading of fluorescent signal 
was apparent for PLGA NPs at 2 h but still clearly present in the case of PEG-PLGA 
NPs, namely throughout the middle and distal sections, which seems to agree with 
quantitative results presented above. Assessment of the maximum distance covered 
by NPs evidenced that PEG-PLGA NPs were able to be transported across 35-40% 
of the length of the colon between 15 min and 2 h post-administration (Fig. 3.12, B). 
Coverage by PLGA NPs was restricted to less than 10% at 15 min and negligible 
after 2 h. Again, these results strongly reinforce the ability of PEG modification to 
provide enhanced distribution and retention of nanosystems following rectal 
administration. Semi-quantitative assessment of particle retention was inferred from 
the total radiance signal from colorectal tissue images (Fig. 3.12, C) and was in 
general agreement with quantitative results previously presented. Differences are 
likely to be related with the intrinsic variability of tissue scattering and absorption, 
which limits precise quantitative assessment of fluorescent signal (43, 44). 
Several limitations of our study should be considered when interpreting 
presented results. Naturally, interspecies differences, namely in GIT anatomy and 
physiology, impair direct transposition of generated data into the human scenario. 
For example, the overall GIT transit time in mice is much faster (45) and, thus, 
presented timeframes for distribution and depletion of NPs are probably wider in 
humans. The use of alternative animal models (e.g., pigs) that are considered closer 
to humans may be of interest in future studies. Furthermore, mice used in this study 
were healthy and are not expected to replicate possible variations in colon motility 
and mucus structure that can occur in models featuring local pathological conditions 
(46, 47). Other natural changes, namely related with digestion in fed animals, may 
impact bowel physiology. It is expected, however, that the distribution and retention 
patterns of NPs reported in the present study may still apply, at least to some extent. 
PEG modification of particles using a non-covalent approach is not exempt of 
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criticism since changes throughout the course of the study, namely regarding surface 
density of poloxamer 407, may have occurred.  
 
 
Fig. 3.12. Qualitative and semi-quantitative assessment of the distribution and retention of 
NPs using NIR imaging. (A) Typical fluorescence signal from excised terminal segments of 
the GIT at 15 min and 2 h following treatment with either Cy7.5-loaded PEG-PLGA NPs or 
Cy7.5-loaded PLGA NPs. Heat map scale ranges from 0.6108 to 10108  p cm2 s1 W1. 
(B) Estimation of the total extension of the colorectal length covered by NPs. (C) Semi-
quantitiative evaluation of the amount of NPs associated with excised tissues. Columns 
represent mean values and bars the SD (n=2-3). (*) denotes a significant difference (p < 
0.05). ND: not detected/not determined.  
 
 
 
However, in vitro data appears to support the considerable resistance of proposed 
PEG-PLGA NPs to surface shedding of poloxamer 407 (Figure 3.6). Moreover, the 
use of such strategy, namely considering drug delivery applications, may facilitate 
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regulatory approval as both PLGA and poloxamers (but not PEG-PLGA copolymers) 
have a long track record of clinical use in drug delivery systems and/or medical 
devices (48). Another question relates to the relatively broad division of the colon in 
three parts, as well as the wide time points considered in this study, which limits the 
precision to which spatial and temporal distribution could be determined. However, 
considering that this has been a relatively unexplored question, it seems reasonable 
that the chosen experimental setup can be helpful in establishing a general overview 
of distribution and retention of NPs upon rectal administration. Also, the inclusion of 
NIR imaging experiments was able to complement time-dependent distribution 
patterns of the different NPs. 
 
 
3.5. Conclusions 
 
We developed and characterized PLGA NPs densely modified at the surface 
with PEG in a non-covalent way. Materials used for production were selected based 
on their well-established safety profile and regulatory status for medical use. Both 
PEG-modified and plain PLGA NPs were shown to reach up to the middle segment 
of the colon but presented diverse behavior upon rectal administration in a healthy 
mouse model. In particular, PEG-PLGA NPs featured enhanced distribution and 
retention as compared to PLGA NPs. These observations were correlated with the 
ability of modified particles to be transported across mucus and reach the epithelial 
lining. We also described for the first time an interesting event regarding the 
distribution dynamics of PEG-PLGA NPs in the distal colon. Early fast depletion of 
administered particles at the terminal part of the colon to adjacent sites is followed by 
later replenishing, presumably proceeding from NPs that initially migrated to the 
middle colon. These circumstances may have implications when considering the use 
of nanoparticulate drug carriers. Overall, our results reinforce previous reports on the 
potential usefulness of mucus-penetrating NPs for mucosal drug delivery. 
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4.1. Abstract  
 
 Antiretroviral drug nanocarriers hold great promise in the development of 
microbicides to be used in the prevention of rectal HIV transmission. However, 
challenges remain namely concerning which properties are more suited for 
enhancing colorectal distribution and retention of candidate microbicide compounds. 
In this work, we developed and assessed the in vitro and in vivo performance of 
poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) as carriers for the 
model drug efavirenz (EFV). We particularly focused on the effects of non-covalent 
polyethylene glycol coating of PLGA NPs (PEG-PLGA NPs) conferring mucus 
diffusive behavior on the pharmacokinetics (PK) of EFV following rectal 
administration to mice.  Drug-loaded PLGA-NPs and PEG-PLGA NPs (200-225 nm) 
were obtained by nanoprecipitation. Both type of systems were able to retain native 
antiretroviral activity of EFV, while featuring lower cytotoxicity against different 
epithelial cell lines and HIV target cells. Also, PLGA-NPs and PEG-PLGA NPs were 
shown to be readily taken up by colorectal cell lines, and mildly reducing EFV 
permeation while increasing membrane retention in Caco-2 and Caco-2/HT29-MTX 
cell monolayer models. When administered to mice in phosphate buffered saline (pH 
7.4), EFV-loaded PEG-PLGA NPs consistently provided higher drug levels in 
colorectal tissues and lavages as compared to free EFV or drug-loaded PLGA-NPs. 
Mean values for the area-under-the-curve between 15 min and 12 h following 
administration were particularly higher for PEG-PLGA NPs in distal and middle 
colorectal tissues, with relative bioavailability values of 3.7 and 29, respectively, as 
compared to free EFV (2.2 and 6.0 over PLGA NPs, respectively). Systemic 
exposure to EFV was reduced for all treatments. NPs were further shown safe after 
once daily rectal administration for 14 days as assessed by histological analysis of 
colorectal tissues and chemokine/cytokine assay of rectal lavages. Overall, PEG-
PLGA NPs demonstrated to be safe carriers for rectal microbicide drug delivery and 
able to provide enhanced local PK that could be of value in preventing rectal HIV 
transmission. 
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4.2. Introduction 
 
 The HIV/AIDS pandemic remains a huge burden to our times with a total 
estimate of over 36 million people living with the infection worldwide by the end of 
2016 (1). Sexual transmission of the virus is accountable for the majority of all new 
cases and URAI represents a considerable fraction of these (2). Although expected 
to occur less frequently than vaginal intercourse, the higher risk of viral transmission 
across the colorectal mucosa as compared to the cervicovaginal mucosa (around 10-
fold) (3), as well as its practice among both MSM and heterosexual women (4, 5), 
makes URAI a relevant contributor to the overall number of new infections. Oral PrEP 
with TDF/FTC for at high risk individuals has been successfully introduced in various 
countries over the last years and is generally considered as highly effective in 
preventing sexual HIV transmission (6). Notwithstanding, oral PrEP presents several 
caveats, raising issues concerning potential ARV resistance, systemic toxicity, 
inconvenient dosage regimens (once daily, irrespective of sexual activity frequency) 
potentially leading to poor adherence, suboptimal levels at ano-genital tissues 
despite high systemic levels, and promotion of risky behavior, among others (7, 8). 
Cost may also impair large scale population coverage, particularly in resource poor 
regions (6). 
Topical PrEP with rectal microbicides may be an appealing alternative or even 
auxiliary strategy to oral PrEP (9), in preventing rectal HIV transmission. Rectal 
microbicides comprise products intended to be self-administered in the rectum 
around the time of sexual intercourse (10). In particular, microbicides present the 
potential to provide a new on-demand protection tool that is able to rapidly yield high 
drug levels at the colorectum with minimal systemic exposure. However, efforts in 
developing rectal microbicides have been scarce and often limited by the inability of 
conventional products – typically designed as gels, suppositories or enemas – to 
allow safe and effective colorectal drug distribution and retention for prolonged time 
periods (11). Alongside other potentially beneficial features (e.g., controlled drug 
release, enhanced interaction with HIV-susceptible host cells), nanotechnology-
based microbicide drug carriers, may help circumventing drug distribution/retention at  
the colorectum, thus enhancing local PK. Such an effect has been shown previously 
for polymeric NPs containing different ARV drugs and administered by the vaginal 
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route (12, 13). However, it is not clear whether the use of nanocarriers could have an 
analogous outcome in the case of rectal delivery. Previous in vivo work by our group 
and others supports that the behavior of mucus-penetrating nanosystems 
administered into the rectum may be particularly beneficial. Dense surface coating of 
polymeric NPs with PEG was shown not only to contribute to the extensive coverage 
of the colorectal epithelial surface (14, 15) but also enhance retrograde transport into 
the proximal end of the colon and provide overall longer particle residence (16). 
In the present work, we developed PLGA-based NPs containing the NNRTI  
EFV and characterized obtained nanosystems, either coated or not with PEG, for 
physicochemical and in vitro biological properties deemed relevant for rectal 
microbicide development. We further tested in vivo safety and the ability of both 
types of NPs to modify the local PK of EFV as compared to the free drug by using a 
mouse model. 
 
 
4.3. Materials and Methods 
 
4.3.1. Materials 
 
 End-capped PLGA with 50:50 D,L-lactide:glycolide ratio and 0.2 dL g-1  
inherent viscosity (Purasorb PDLG 5004) was kindly provided by Corbion 
(Gorinchem, The Netherlands), EFV (315.68 g mol-1) by BDR Lifesciences 
(Vadodara, India) and poloxamer P407 (Kolliphor® P 407) by BASF (Ludwigshafen, 
Germany). Coumarin 6 (C6), polysorbate 80 (Tween® 80), and phosphate buffered 
saline (PBS) tablets were obtained from Sigma-Aldrich (Schnelldorf, Germany and 
Lyon, France, respectively). Acetone was purchased from Fisher Scientific 
(Leicestershine, UK). Ultrapure water used was obtained in-house using a Milli-Q 
purification system (Merck Millipore, Darmstadt, Germany). All other solvents and 
chemicals were of analytical grade or equivalent. 
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4.3.2. Production  and physicochemical characterization of nanoparticles 
 
 PLGA-based NPs were produced by a nanoprecipitation method as described 
previously (16). Briefly, 20 mg of PLGA were dissolved in 1 mL of acetone and added 
to 20 mL of an aqueous solution of poloxamer 407 (0.1%, w/v) under magnetic 
stirring by slowly injecting it using a syringe coupled with a 23G needle. When 
relevant, one milligram of EFV or 0.08 mg of C6 were co-dissolved with PLGA in 
acetone in order to obtain EFV-loaded NPs or fluorescent NPs, respectively. In all 
cases, NPs were collected after 3 h of stirring at room temperature and washed twice 
with 10 mL of water using a filter tube with a MW cut-off of 100 kDa (Amicon Ultra 
filter, Ultracel membrane with 100,000 MWCO, Millipore Corporation, Bedford, MA, 
USA) at 167 g. NPs were incubated for 12 h with 1% (w/v) poloxamer 407 aqueous 
solution in order to obtain PEG-PLGA NPs. NPs suspensions were centrifuged one 
more time as described above in order to remove excess poloxamer and to 
concentrate NPs. Non-modified NPs (PLGA NPs) were treated in the same way by 
replacing the poloxamer solution by water. NPs were further freeze-dried whenever. 
NPs dispersed in 10 mM sodium chloride at approximately 0.2 mg mL-1 were 
characterized at 25 ˚C regarding size, size distribution and ZP by using a Zetasizer 
Nano ZS (Malvern Instruments, Worcestershire, UK). The association efficiency (AE) 
and drug loading (DL) of EFV into NPs were calculated as: 
 
 
ܣܧ (%) =  
ܫ݊݅ݐ݈݅ܽ ܧܨܸ − ܴ݁ܿ݋ݒ݁ݎ݁݀ ܧܨܸ
ܫ݊݅ݐ݈݅ܽ ܧܨܸ
 ݔ 100 
(Eq. 4.1) 
ܦܮ (%) =  
ܫ݊݅ݐ݈݅ܽ ܧܨܸ − ܴ݁ܿ݋ݒ݁ݎ݁݀ ܧܨܸ
ܫ݊݅ݐ݈݅ܽ ܧܨܸ & ܲܮܩܣ
 ݔ 100 
(Eq. 4.2) 
 
where Initial EFV and Initial EFV & PLGA are the amounts of drug and drug plus 
polymer used to produce NPs, respectively. Recovered EFV refers to the amount of 
drug recuperated from filtrates collected during purification of NPs and quantified by 
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an high-performance liquid chromatography with UV detection (HPLC-UV) method as 
described in 4.3.2.1.  
Surface morphology of NP samples treated with uranyl acetate was assessed 
by TEM using a JEM-1400 Electron Microscope (JEOL, Tokyo, Japan) at 80 kV. In 
vitro drug release was performed under sink conditions by placing NPs 
(corresponding to 213 µg of EFV) into 15 mL of 3% (w/v) polysorbate 80 in PBS (pH 
7.4) at 37 °C and 100 rpm orbital shaking. Release medium samples (0.2 mL) were 
collected periodically from 15 min to 6 h, centrifuged at 15,000 g and the 
supernatant assayed for EFV by HPLC-UV. Initial volume was replenished with fresh 
release medium.  
 
 
4.3.2.1. HPLC-UV method for efavirenz assay 
 
HPLC-UV was used to quantify EFV in different matrices. A reversed-phase 
method was developed in isocratic mode using a C8 reverse-phase analytical column 
(Symmetry® LC, 5 µm particle size, 4.6 mm internal diameter, 25 cm length; Waters, 
Milford, MA, USA). The mobile phase consisted of acetonitrile (ACN) and 10 mM 
acetate buffer solution pH 4.0 (70:30, v/v). The flow rate was maintained at 1 mL min-
1 and the injection volume was 10 µL. EFV was detected at 247 nm with retention 
time of 7.2 min. Calibration curves were generated from known standards of EFV in a 
mixture of ACN and water (1:1). The method was determined to be linear in the 
range of 1.0 to 50.0 µg mL-1 (r20.999 for linear least squares regression). For 
samples resulting from in vitro permeability experiments, injection volumes were 
increased to 50 µL and linearity established from 0.1 to 10 µg mL-1 (r20.999). Also, 
the mobile phase needed to be adjusted to 43:57 (v/v) since polysorbate 80, the 
surfactant used to assure sink conditions, has a broad spectrum of UV-Vis absorption 
and affected the EFV peak at original conditions (17). In this case, the retention time 
of EFV was 13.8 min.  
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4.3.3. Cell lines and culture conditions 
 
 Human colonic epithelial Caco-2 (C2BBe1 clone) cell line was purchased from 
ATCC (Manassas, VA, USA) and used at passages 54-63. Human colonic epithelial 
HT29-MTX (passages 27-43) and SW480 (passages 13-15) cell lines were kindly 
provided by Dr. T. Lesuffleur (INSERM U178, Villejuif, France) and Dr. M. Grade 
(University of Göttingen, Germany), respectively. TZM-bl cells were acquired from 
NIH AIDS Reagent Program (Germantown, MD, USA). PBMCs were isolated from 
buffy coats of healthy adult donors by density gradient centrifugation using Ficoll® 
Paque Plus (GE Healthcare, Waukesha, WI, USA) followed by stimulation with 5 μg 
mL-1 of phytohemagglutinin (Sigma-Aldrich, St. Louis, MO, USA) in culture medium 
for 72 h. 
Caco-2, HT29-MTX and SW480 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) with ultraglutamine (Lonza, Vervieres, Belgium) 
supplemented with 10% (v/v) fetal bovine serum (FBS; Biochrom, Berlin, Germany), 
100 U mL-1 penicillin and 100 μg mL-1 streptomycin (BioWest, Nuaillé, France), and 
1% (v/v) non-essential aminoacids, 100 concentrate (Biochrom). TZM-bl were 
cultured in DMEM supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 U mL-1 
penicillin and 100 μg mL-1 streptomycin, 1 mM sodium pyruvate, and 1 mM non-
essential aminoacids, all acquired from Gibco/Invitrogen (Carlsbad, CA, USA). 
PBMCs were maintained in RPMI-1640 medium (Gibco/Invitrogen) supplemented 
with 10% (v/v) FBS (Gibco/Invitrogen), 2 mM L-glutamine (Gibco/Invitrogen), 100 U 
mL-1 penicillin and 100 μg mL-1 streptomycin (Gibco/Invitrogen), 0.3 mg mL-1 
gentamicin (Gibco/Invitrogen), 5 µg mL-1 polybrene (Sigma-Aldrich) and 20 U mL-1 
recombinant interleukin-2 (NIH AIDS Reagent Program). All cells were maintained at 
95% RH, 37 °C and 5% CO2. 
 
 
4.3.4. Cytotoxicity of nanoparticles 
 
 Cytotoxicity of NPs to epithelial colorectal cell lines Caco-2, HT29-MTX and 
SW480 was assessed using the triazolyl blue tetrazolium bromide (MTT) metabolic 
activity assay. Each cell line was individually seeded in 96-well plates at 
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concentrations of 104 cells/well (HT29-MTX and SW480) or 2  104 cells/well (Caco-
2) for 24 h and further incubated with different concentrations of NPs or free EFV. 
Media only and 1% (w/v) Triton X-100 were used as controls. After 24 h of 
incubation, cells were washed twice with PBS, pH 7.4, followed by the addition of 200 
μL per well of MTT solution (0.5 mg mL-1 in medium) and incubation for 4 h. Medium 
was then removed and 200 μL of dimethyl sulfoxide (DMSO) were added in order to 
dissolve newly formed formazan crystals. Absorbance was determined at 590 nm 
with 630 nm background deduction. 
In the case of TZM-bl cells and PBMCs, cytotoxicity was determined using the 
resazurin reduction assay. Cells were individually seeded in 96-well plates at 
concentrations of 104 cells per well (TZM-bl) or 2  105 cells per well (PBMCs) and 
incubated for 24 h. NPs or free EFV were then added at different concentrations for 
48 h (TZM-bl) or 14 days with medium being re-freshen at day 3, 7 and 10 (PBMCs). 
Media only and 5% (w/v) sodium dodecyl sulfate (SDS) were used as controls. 
Afterwards, 10 μL of resazurin solution (alamarBlue™, Invitrogen) were added to 
each well and cells incubated for an additional 4 h. Fluorescence was determined at 
530-560/590 nm. 
Experiments were performed in duplicate (TZM-bl cells and PBMCs) or 
triplicate (Caco-2, HT29-MTX and SW480 cells). Results were calculated as 
percentage cell viability (cells incubated with medium only considered as 100% 
viability) and half maximal cytotoxic concentration (CC50) values were calculated from 
cell viability vs. drug concentration plots using the sigmoidal dose-response (variable 
slope) model of Prism® (v. 5.01, GraphPad Software, San Diego, CA, USA). 
 
 
4.3.5. Antiretroviral activity  
 
 Antiviral activity of NPs and free EFV was assessed using a Tat-regulated 
LTR-driven luciferase reporter gene assay in TZM-bl cells as previously described 
(18). Briefly, TZM-bl cells (104 cells/well) were incubated with serial 10-fold dilutions 
of NPs or free EFV in medium supplemented with 19.7 g mL-1 diethylaminoethyl-
dextran for 1 h before infection with 400 TCID50 (half-maximal tissue culture infectious  
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dose) of HIV-1SG3.1 or 200 TCID50 HIV-1NL4-3 isolates (19). NPs or free EFV were 
present during incubation with the virus. After 48 h of infection, luciferase expression 
was determined using the Pierce™ Firefly Luc One-Step Glow Assay Kit (Thermo 
Scientific, Waltham, MA, USA) according to the instructions of the manufacturer. The 
relative light units (RLUs) were measured using a microplate luminescence reader 
(Infinite® M200; Tecan, Grödig, Austria). Cells non-exposed or exposed to the virus 
were used as the 100% and 0% inhibition controls, respectively, in the absence of 
EFV. Two independent experiments were performed for each compound and each 
assay was done in triplicate wells. The half-maximal and 90% inhibitory 
concentrations (IC50 and IC90, respectively), as well as the dose-response curve 
slopes (Hill slope), were estimated by plotting the percent inhibition of infection (y-
axis) against the log10 drug concentration (x-axis) using the sigmoidal dose-response 
(variable slope) equation in Prism® 5.01 software (GraphPad Software, La Jolla, CA, 
USA). Complementary cell viability assays using the resazurin reduction assay as 
detailed in 4.3.4. were performed for TZM-bl cells in order to calculate CC50, SI 
(defined as the CC50/IC50 ratio) and relative selectivity index (RSI; defined as the SI 
of NPs/SI of free EFV ratio) values. 
 
 
4.3.6. Cell uptake of nanoparticles 
 
 Uptake of fluorescent NPs by Caco-2 and HT29-MTX cells was assessed 
qualitatively and quantitatively by fluorescence microscopy and flow cytometry, 
respectively. Caco-2 or HT29-MTX cells were seeded in 6-well plates (0.5 - 1.0  106 
cells per well) and on top of a microscope coverslip. After 24 h in culture, fluorescent 
NPs were dispersed in medium at a concentration of 0.01% (w/v) and incubated with 
cells for 15 min and 2 h. Cells were then washed twice with PBS, stained with 
CellMask™ Orange (Life Technologies, Eugene, OR, USA), re-washed with PBS and 
fixed with 2% (v/v) paraformaldehyde. Staining with DAPI (Sigma-Aldrich) was further 
performed. Coverslips containing adherent cells were mounted in slides using 
Vectashield® antifade mounting media (Vector Laboratories, Burlingame, CA, USA). 
Qualitative assessment of cellular uptake was performed using an Axiovert 200M 
inverted fluorescent microscope (Carl Zeiss, Göttingen, Germany). Cross-sectional 
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imaging of cells along the z-axis was performed in order to better assess NPs 
localization, namely to differentiate between actual intracellular uptake and simply 
cell membrane adsorption. In the case of quantitative evaluation, cells were 
incubated with NPs similarly to qualitative studies but without using coverslips. After 
incubation and twice PBS washing, cells were collected using trypsin-EDTA (Sigma-
Aldrich, Lyon, France), transferred to 1.5 mL Eppendorf tubes and centrifuged at 520 
g (7 min, 4 °C). Cell pellet was washed with PBS, fixed with 2% (v/v) 
paraformaldehyde, re-washed with PBS and finally re-suspended in PBS before 
storage at 4 °C until further analysis. The quantification of cell-associated fluorescent 
signal was performed by flow cytometry using a BD FACS Calibur™ system (BD 
Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FlowJo® 
software v10.0.7 (Tree Star, Ashland, OR, USA). 
 
 
4.3.7. Drug permeability and retention in colorectal cell monolayers 
 
 Permeability and retention of EFV, either free or associated to NPs, in Caco-2 
and in Caco-2/HT29-MTX co-culture cell monolayer models was assessed as 
previously described (20). Briefly, Caco-2 cells alone or in combination with HT29-
MTX cells in a proportion of 90:10 were seeded at a density of 105 cells cm-2 onto 3.0 
µm transparent polyethylene terephthalate membrane Transwell® inserts with a cell 
growth area of 0.90 cm2 (Corning, Durham, NC, USA). Cells were maintained in 
culture for 21 days for monolayer formation and maturation, with medium being 
changed twice weekly. Growth and integrity of mono- and co-culture monolayers was 
monitored by measuring the transepithelial electrical resistance (TEER) using an 
EVOM2 voltohmmeter equipped with a STX2 electrode (World Precision Instruments, 
Sarasota, FL, USA). TEER values were calculated by subtracting the resistance of a 
blank (cell-free culture insert with medium) to experimental values, and correcting for 
the surface area. On the day of experiments, the medium was removed from the 
apical and basolateral compartments and the cells were washed twice with Hanks' 
Balanced Salt Solution (HBSS; Gibco, Waltham, MA, USA). Fresh HBSS was added 
to both compartments and the system was allowed to equilibrate for 30 min at 37 °C. 
HBSS from the receptor compartment contained 0.2% (w/v) poloxamer 407 in order 
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to maintain sink conditions. Then, HBSS from the apical compartment was replaced 
by 0.5 mL of EFV-loaded NPs or free EFV dispersed in HBSS at a final drug 
concentration of 0.016% (w/v). Transwell® inserts were kept under orbital shaking 
(100 rpm) at 37 °C throughout the experiment. TEER was also monitored before 
experiments and at each time point to assure the viability and cell monolayer integrity 
during the entire assay. Samples of 200 µL were collected at pre-defined time points 
from basolateral compartments, assayed for EFV by HPLC-UV as described above, 
and replaced with the same volume of fresh HBSS. After the last time point, media 
were removed from both compartments of the Transwell® system and cells were 
washed twice with HBSS. The insert was isolated from the Transwell® system and 
EFV extracted from the cell monolayer by immersion in 0.5 mL of DMSO overnight 
under shaking (150 rpm). The amount of drug recovered from the basolateral 
(receptor) media from 15 min to 4 h was used to calculate apparent permeability 
coefficient (Papp) values in cm s-1 as follows:  
 
ୟܲ୮୮ =  
ܳ
ܣ × ܥ଴ × ݐ
 
(Eq. 4.3) 
 
where Q is the total amount of drug that permeated the cell monolayer (μg), A is the 
diffusion area (cm2), C0 is the initial concentration of drug (μg cm3), and t is the time 
of experiment (s). The coefficient Q/t represents the steady-state flux of drug across 
the cell monolayer. The permeability enhancement ratio (PER) was calculated by 
dividing mean values of Papp of EFV when associated to NPs by Papp of the free drug. 
The amount of EFV associated to cell monolayers was also determined at the end of 
the experiment. 
 
 
4.3.8. Pharmacokinetics and safety studies 
 
All animal experiments were approved by the Ethics Committee at Instituto 
Universitário de Ciências da Saúde (process no. 01/ORBEACESPU/2014) and 
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conducted under European Directive 2010/63/EU guidance. Male CD-1 IGS mice 
(Harlan, Barcelona, Spain) were used between 8-12 weeks old. 
Local and systemic PK of EFV were assessed over 12 h after rectal 
administration of EFV-loaded NPs or free drug at a total dose of 40 µg of EFV. 
Animals were fasted for 24 h before experiments, with free access to water, and the 
rectum was gently flushed with 200 µL of deionized water at 30 min prior to rectal 
administration in order to reduce and soften the consistency of fecal content. Timing 
of this last procedure also allows for the mucus layer to be replenished before 
administration of NPs or EFV (14). NPs or the free drug were dispersed in isotonic 
PBS (pH 7.4) and 20 µL (corresponding to 40 µg of EFV) administered intrarectally 
using a 200 µL pipette tip. Mice were sacrificed at pre-defined time points from 15 
min to 12 h following administration by overdose of inhalational isoflurane followed by 
intracardiac exsanguination. Blood was collected into Vacuette® tubes containing 
K3EDTA (Greiner Bio-One GmbH, Kremsmünter, Austria), centrifuged (496 g, 10 
min, 4 °C) and the plasma recovered. Proximal, middle and distal/rectum segments 
of the colon were collected, weighted and individually washed with 350 µL of PBS. 
Plasma, as well colon tissue segments and washing fluids, were stored at -80 °C until 
further processing. All biological samples were processed and analyzed by a HPLC 
method coupled to tandem mass spectrometry detection (HPLC-MS/MS) method 
(see section 4.3.8.1). 
Safety of NPs was assessed upon once daily rectal administration for 14 days 
to mice. NPs or the free drug were administered intrarectally as indicated for PK 
studies. Mice treated similarly with PBS only, 2% (w/v) N-9 (21) or without any 
treatment were used as controls. Animals were monitored daily for discomfort or 
behavioral changes, body weight and macroscopic alterations at the anal region. The  
rectum was flushed with 550 µL of PBS at 30 min prior to each administration, and 
lavage samples were centrifuged (13,414 g, 10 min, 4 °C) and supernatants stored 
at -80 ˚C until further use. The same procedure was also performed following mice 
sacrifice (inhalational isoflurane overdose), 24 h after the last administration. The 
colon was also collected following euthanasia, roughly divided in three equal sized 
segments (proximal, middle and distal/rectum) as previously described, processed 
for hematoxylin and eosin (H&E) staining, and analyzed for histological features. 
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Rectal lavages were analyzed for interleukin (IL)-1, IL-6, interferon gamma (IFN-) 
and tumor necrosis factor alpha (TNF-) levels by an ELISA-based 
chemiluminescent multiplex assay (Quansys Q-Plex™ Cytokine Array, tebu-bio, Le 
Perray en Yveline, France). All treatments were performed in three animals. 
 
 
4.3.8.1. Quantification of efavirenz from biological samples by HPLC-
MS/MS 
 
The quantification of EFV in samples resulting from mouse studies was 
performed by using a previously described and validated HPLC-MS/MS (22), as 
briefly detailed in the following. The mobile phase contained two components, 
namely 0.1% (v/v) formic acid in water and 0.1% (v/v) formic acid in ACN that were 
filtered through a 0.22 μm Millipore GVWP filter and a 0.45 μm Millipore HVHP filter, 
respectively, and degassed in an ultrasonic bath for 15 min before use. EFV 
purchased from Sigma-Aldrich and deuterated efavirenz-d5 (EFV-d5) obtained from 
Toronto Research Chemicals Inc. (Toronto, ON, Canada), through LGC standards 
(Barcelona, Spain) were used as standard and internal standard (IS), respectively. 
HPLC-MS/MS analysis was performed in a Nexera X2 UHPLC system coupled to a 
triple quadrupole LCMS-8040 mass spectrometer equipped with an electrospray 
ionization source (ESI) (Shimadzu Corporation, Kyoto, Japan). Chromatographic 
separation was achieved using a reversed phase Mediterranea sea C18 column (3 
m, 100 x 2.1 mm; Teknokroma, Barcelona, Spain) at 45 C and elution was 
performed in gradient mode, at total flow rate of 0.35 mL min-1, according to the 
program established previously (22). During each chromatographic run, the column 
eluate was directed to MS interface between 3.60 and 4.55 min. The mass 
spectrometer was operated in negative ionization mode (ESI-) and data were 
acquired in selected reaction monitoring (SRM) mode (EFV, m/z 314.00 > 68.95, m/z 
314.00 > 244.05; EFV-d5, m/z 319.00 > 68.90, m/z 319.00 > 247.95). Calibration 
curves were established with EFV standard solutions prepared at final concentrations 
of 4, 10, 20, 50, 100, 200, 350 and 500 ng mL-1 in ACN-water (50:50, v/v). Prior to 
analysis, tissue extracts in ACN were evaporated to dryness under a gentle stream of 
nitrogen and re-suspended in 500 µL of ACN-water (50:50, v/v). Lavage and blood 
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plasma extracts were diluted 1:5 using the same solvent. EFV-d5 was added to each 
standard solution and sample extract in order to reach the final concentration of 400 
ng mL-1. The injection volume was 5 µL. 
Matrix effect was evaluated for EFV and corresponding IS by comparing the 
peak area obtained in spiked blank matrix extracts (200 ng mL-1 of EFV and 400 ng 
mL-1 of EFV-d5) with the peak area obtained for the same concentration of analytes in 
ACN-water (50:50, v/v) (Table 4.1). The extraction efficiency of target analyte and IS 
was evaluated for the different biological matrices (Table 4.2). The recovery from 
colorectal tissues was assessed by spiking the tissues with 1 g of EFV and 2 g of 
EFV-d5 per g of matrix, before extraction. In the case of lavage and plasma samples, 
2 g of EFV and 4 g of EFV-d5 were added per mL of fluid before sample 
processing. The percentage of recovery was obtained by comparing the peak area of 
spiked samples with the peak area of standard solutions prepared at the same 
concentration. 
 
 
Table 4.1. Matrix effect evaluation for the analysis of EFV in tissue, lavage and plasma 
extracts. 
Matrix 
Matrix factor (EFV)a 
 
Matrix factor (IS)a 
 IS normalized 
matrix factora,b 
Mean (%) CV (%)  Mean (%) CV (%)  Mean (%) CV (%) 
Distal colon tissue 93.6 7.0  97.5 6.1  96.0 0.9 
Middle colon tissue 93.8 0.8  100.3 1.9  93.5 1.1 
Distal colon lavage 94.6 4.5  98.2 7.4  96.4 2.9 
Middle colon lavage 97.2 0.5  97.0 1.0  100.3 0.5 
Blood plasma 91.8 0.1  94.1 1.7  97.6 1.6 
a The matrix effect was evaluated for two different blanks of each biological matrix (n=2); b IS normalized matrix 
factor was calculated by division of the matrix factor of the analyte by the matrix factor of the IS. 
 
 
Limits of detection (LOD) and quantification (LOQ) of EFV for each matrix 
were determined as the concentration values that originated a signal-to-noise ratio in 
analytical chromatograms of 3:1 and 10:1, respectively (Table 4.3). Different PK 
parameters were determined namely maximum concentration (Cmax) and time at 
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which it occurred (tmax), area under the concentration-time curve between 15 min and 
12 h (AUC0.25-12h) and relative bioavailability (Frel) as compared to the free drug, as 
previously described (13). Groups of five animals were used for all experimental 
conditions (treatments and time points). 
 
 
Table 4.2. Extraction efficiency of EFV and corresponding IS from biological matrices. 
Matrix 
Target concentration on 
final extract 
(ng mL-1) 
Recovery (EFV)a  Recovery (IS)a 
Mean (%) CV (%) 
 
Mean (%) CV (%) 
Distal colon tissue 200 95.2 3.2  99.6 1.6 
Middle colon tissue 200 91.2 7.0  94.6 4.3 
Distal colon lavage 200 92.6 9.6  95.9 5.6 
Middle colon lavage 200 92.9 5.1  99.8 1.1 
Blood plasma 200 98.0 1.8  90.1 2.0 
a The extraction efficiency of EFV and IS was assessed for three different tissue samples (n=3) and two different 
lavage and plasma samples (n=2). 
 
 
 
Table 4.3. Limits of detection (LOD) and quantification (LOQ) of EFV determined for tissues, 
fluids and blood plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 LOD (µg.L-1) LOQ (µg.L-1) 
DC fluid 6 12 
MC fluid 5 11 
DC tissue 4 8 
MC tissue 3 7 
Blood plasma 3 8 
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4.3.9. Statistical analysis 
 
 Analysis was performed in Prism® 5.01 software using Student’s t-test for two 
group comparisons or one-way ANOVA with Bonferroni's Multiple Comparison Test. 
Experiments were performed in triplicate, except if noted otherwise, and values of 
p<0.05 were accepted as denoting significance. Data is presented as mean  SD 
values, except for in vivo results in which error is described as the standard error of 
the mean (SEM). 
 
 
4.4. Results and Discussion 
 
4.4.1. Production and physicochemical properties of nanoparticles  
 
 The major motivations underlying this work were to explore the potential 
benefit of nanotechnology for the development of microbicide drug carriers and to 
contribute for the ongoing debate regarding the use of either mucoadhesive or 
mucus-inert nanosystems for mucosal drug delivery (23). In order to pursuit these 
goals, we proceeded with the production of EFV-loaded PLGA NPs followed by 
surface modification with poloxamer 407. EFV was chosen as a model microbicide 
drug not only because of its intrinsic potent ARV activity and acceptable safety 
profile, but also due to its intrinsic physicochemical properties, namely low aqueous 
solubility, which are challenging in terms of more conventional formulation in 
aqueous media. Furthermore, EFV shares these attributes and limitations with other 
drugs that are in more advanced stages of microbicide development, particularly 
dapivirine (24), thus making it a good surrogate. The choice of nanocarrier type and 
its manufacturing technique took into consideration factors such as regulatory status, 
availability and affordability of used materials, as well as potential for manufacturing 
scalability, in order to yield systems that could realistically move forward as putative 
anti-HIV microbicide candidates. 
EFV-loaded PLGA NPs were successfully produced by nanoprecipitation and 
further modified using poloxamer 407. Incubation of polymeric NPs with this type of 
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triblock copolymers comprising PEG and PPG chains (PEG-PPG-PEG) allows 
obtaining nanosystems featuring a non-covalent PEG corona (25). In particular, 
poloxamer 407 used at 1% (w/v) is able to confer densely PEG-coated NPs that 
hinder interactions with mucus (26) and, more importantly, enhance the distribution 
and retention of these nanosystems following rectal administration in mice (16). 
Obtained EFV-loaded PLGA NPs and EFV-loaded PEG-PLGA NPs, as well their 
blank and C6-loaded (fluorescent) counterparts, presented average hydrodynamic 
diameters around 200-225 nm and narrow size distribution (Table 4.4). Main 
differences concerned ZP, varying from slightly negative for PLGA NPs to near 
neutral for PEG-PLGA NPs, respectively. The near neutral charge for PEG-PLGA 
NPs is indicative of the dense coating of NPs surface with poloxamer 407 as 
previously demonstrated (16).   
 
 
Table 4.4. Physicochemical properties of NPs. Hydrodynamic diameter (HD), polydispersity 
index (PdI), zeta potential (ZP), association efficiency (AE) and drug loading (DL) of EFV-
loaded PLGA NPs. Results are presented as mean ± SD (n=3). 
Nanosystem Payload HD (nm) PdI ZP (mV) AE (%) DL (%) 
PLGA NPs EFV 217 ± 4 0.072 ± 0.002 -6.6 ± 0.6 85.9 ± 2.6 4.3 ± 0.1 
 None 200 ± 2 0.087 ± 0.006 -6.6 ± 0.9 – – 
 C6 221 ± 10 0.087 ± 0.029 -4.7 ± 0.1 ND ND 
PEG-PLGA NPs EFV 223 ± 3 0.101 ± 0.009 -2.0 ± 0.1 83.2 ± 3.6 4.2 ± 0.2 
 None 204 ± 5 0.070 ± 0.009 -2.0 ± 0.3 – – 
 C6 216 ± 2 0.075 ± 0.004 -1.9 ± 0.1 ND ND 
ND: not determined. 
 
 
Association of EFV was high for both types of NPs (>80%), resulting in total DL 
values of around 4%. TEM imaging revealed the spherical shape of NPs and 
confirmed size and size distribution values obtained by DLS (Figure 4.1, A-D). Fast 
release of EFV from NPs was observed under sink conditions (nearly 60% of total 
payload within the first hour), followed by slow release up to at least 6 h (Figure 4.1, 
E). Although often seen as detrimental, such burst release following administration 
may be biologically relevant given the typical use of rectal microbicides as on-
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demand products (i.e., around the time of sexual intercourse) and the need for at 
least partial immediate availability of the drug for exerting its antiviral activity. 
 
 
 
Figure 4.1. Morphology and in vitro drug release profile of NPs. Representative TEM images 
of (A) EFV-loaded PLGA NPs, (B) EFV-loaded PEG-PLGA NPs, (C) blank (no drug) PLGA 
NPs, and (D) blank PEG-PLGA NPs (scale bars = 500 nm). (E) Release profile of EFV from 
PLGA NPs and PEG-PLGA NPs over 6 h in PBS (pH 7.4) added with 3% polysorbate 80 
(w/v). Results are presented as mean ± SD (n=3). 
 
 
 
4.4.2. Cytotoxicity and antiretroviral activity of nanoparticles 
 
 Assuring the potential safety of delivery systems is essential even at early 
stages of the microbicide development pipeline and this can be performed by using 
relevant cell-based models (10). Since EFV induces cytotoxic effects mainly due to 
oxidative stress at the mitochondria (27), MTT and resazurin tests were selected for 
the present study. The in vitro metabolic activity of different colorectal epithelial cell 
lines (Caco-2, HT29-MTX and SW480) and PBMCs, used as proxy for HIV target 
cells, was assessed following exposure to free EFV or drug-loaded NPs. The CC50 
values calculated from viability vs. drug concentration plots are presented in Table 
4.5. The presence of both types of NPs appeared to have no toxic effects on tested 
cells over the range of concentrations evaluated and up to 100 M (expressed as 
EFV concentration). In contrast, free EFV was able to decrease cell viability at lower 
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concentrations, featuring CC50 values typically in the range of 10-20 M. Such 
apparent reduction of the cytotoxicity of EFV upon association to nanocarriers has 
been reported (28, 29) and may be related to the lower amount of free compound for 
triggering toxic effects at the cytoplasm level.  
 
  
Table 4.5. Cytotoxicity potential of EFV-loaded NPs. CC50 values in M and expressed as 
EFV content for the free drug and drug-loaded NPs when tested using different colorectal 
epithelial cell lines and PBMCs. Results are presented as mean ± SD (n=2-3). 
 Caco-2 HT29-MTX SW480 PBMCs 
EFV  14.4 ± 2.3 14.2 ± 2.0 16.3 ± 5.1 27.0 ± 5.9 
PLGA NPs ˃100 ˃100 ˃100 ˃100 
PEG-PLGA NPs ˃100 ˃100 ˃100 ˃100 
 
 
We further conducted in vitro assays in order to assess the impact of using 
EFV-loaded NPs on TZM-bl cell infection by two HIV-1 strains. Results for IC50 and 
IC90 are presented in Table 4.6 and show that both types of EFV-loaded NPs 
displayed potent antiviral activity which was only slightly lower than the free drug. 
Importantly, drug-loaded NPs displayed markedly lower toxicity to TZM-bl cells as 
compared with the free drug (CC50 = 22  1 M), thus rendering overall higher SI 
values and being indicative of better safety profiles. Interestingly, EFV-loaded PEG-
PLGA NPs also presented mildly higher CC50 values in TZM-bl cells than EFV-loaded 
PLGA-NPs (>1,000 µM vs 576  47 µM).  
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Table 4.6. Activity of EFV-loaded NPs against HIV-1. Values of half maximal inhibition concentration (IC50) and 90% inhibition concentration 
(IC90) for free EFV and drug-loaded NPs against infection of TZM-bl cells by HIV-1SG3.1 or HIV-1NL4-3. Results are expressed as EFV 
concentration and presented as mean ± SD (n=2). Selectivity index (SI) and relative selectivity index (RSI) values are dimensionless and 
were calculated using mean IC50 and CC50 values. 
  HIV-1SG3.1  HIV-1NL4-3 
IC50 (nM) IC90 (nM) SI RSI  IC50 (nM) IC90 (nM) SI RSI 
EFV 0.12 ± 0.07 22 ± 10 0.2106 –  0.001 ± 0.001 45 ± 15 16106 – 
PLGA NPs 0.98 ± 0.30 32 ± 10 0.6106 3.2  0.018 ± 0.022 68 ± 15 32106 1.9 
PEG-PLGA NPs 0.73 ± 0.22 37 ± 2 >1.4106 >7.4  0.022 ± 0.024 74 ± 13 >45106 >2.7 
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4.4.3. Nanoparticle uptake and drug permeability/retention in epithelial 
colorectal cell-based models 
 
 We proceeded our investigation by further studying the interactions between 
NPs and epithelial cells. Although not susceptible to viral infection, such cells 
comprise the bulk of the colorectal lining, thus potentially participating indirectly in 
HIV transmission (e.g., occurrence of breaches that provide direct access of the virus 
to the underlying lamina propria) and having an important role in determining local 
and systemic PK. Uptake studies by epithelial cells were conducted using fluorescent 
NPs. The incorporation of C6 did not affect substantially the colloidal properties of 
matching NPs (Table 4.4). Also, leaching of the fluorescent dye was determined to 
be minimal as tested in vitro under sink conditions (<4% after 24 h in PBS pH 7.4 at 
37 °C), which essentially assures its co-localization with NPs. Uptake occurred 
rapidly for both PLGA NPs and PEG-PLGA NPs, either by enterocyte-like Caco-2 or 
mucus-producing HT29-MTX cells, as assessed by fluorescent microscopy (Figure 
4.2, A-B & D-E). Images from z-stacking confirmed cell internalization of NPs that 
seemed to be mainly localized at the cytoplasm. Data from flow cytometry analysis 
indicated that the uptake of both type of particles increased over time but was 
generally higher in the case of PEG-PLGA NPs (around 2- to 4-fold increase over 
PLGA NPs). Reasons for such distinct differences are not clear. For instance, the 
production of mucus by HT29-MTX cells in the reduced timeframe of the experiment 
does not seem to be sufficient to yield a relevant barrier to PLGA NPs diffusion (30). 
One possible explanation for enhanced uptake of PEG-PLGA NPs may reside in the 
ability of poloxamers to interfere with the microviscosity/fluidity of cell membranes by 
a mechanism that is not completely understood (31).   
The impact of NPs on permeability and retention of EFV was also assessed by 
using two cell monolayer models developed by our group (20). Both models are 
based on colorectal Caco-2 cells, reflecting the basic structure of the colorectal 
epithelium. Furthermore, the incorporation of HT29-MTX cells allows sustaining the 
production of mucus (32). Drug permeability profiles across both were used to 
calculate Papp and PER values, as presented in Table 4.7.    
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Figure 4.2. Qualitative (fluorescence microscopy) and quantitative (flow cytometry) 
assessment of NP uptake by (A-C) Caco-2 and (D-F) HT29-MTX colorectal cell lines. 
Representative microscopy images were acquired at magnification 100 after 15 min of 
incubation. Range in z-axis is 7 m. Green, blue and red signals are from C6 (associated 
with NPs), DAPI (DNA) and CellMask™ Orange (cell membrane), respectively. Data for flow 
cytometry are presented as mean ± SD (n=3). (*) denotes a significant difference (p<0.05). 
 
 
 
Results for the free drug are in general agreement with those previously published, 
with differences likely related to variations in experimental settings (Figure 4.3, A-B) 
(33, 34). The use of EFV-loaded NPs led to a mild decrease in permeability as 
compared to the free drug, which could potentially contribute to decreased absorption 
and systemic bioavailability following in vivo administration. These results may reflect 
the delayed drug availability due to the need for EFV to be release from NPs. 
Comparison between data for the two models further showed no difference between 
Papp values for free EFV or each NP formulation. 
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Figure 4.3. Membrane permeability and retention of EFV in colorectal cell monolayer 
models. Drug permeability profile across (A) Caco-2 cell monolayers and (B) Caco-2/HT29-
MTX cell co-culture monolayers. (C) Retention of EFV in Caco-2 and Caco-2/HT29-MTX cell 
monolayers after 4 h of incubation. Data are expressed as mean ± SD percentage values of 
initial amount of EFV in the donor (apical) compartment (n=3). (a) and (b) denote a significant 
difference (p<0.05) when compared with the free drug or PLGA NPs, respectively. 
 
 
 
Such observations, however, do not necessarily mean that the presence of mucus 
(although in scarce amounts (32)) does not play a role in drug/NP transport since 
other factors such as drug release/dissolution dynamics, as well as cell monolayer 
tightness, NP uptake and drug accumulation may play important roles in the 
permeability phenomena (35). Regarding the accumulation of EFV at cell 
monolayers, only mild differences were observed in the co-culture model, with slightly 
higher retention being observed in the case of NPs (Figure 4.3, C). This could reflect 
the intimate association between NPs and the portion of mucus that was not 
completely removed during washing. Overall and in the absence of complex luminal 
transport phenomena occurring only in vivo (14-16), data suggest that both types of 
NPs have little effect on the permeability and retention of EFV. 
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Table 4.7. Drug permeability across colorectal epithelium models as mediated by NPs. 
Apparent permeability coefficient (Papp) and permeability enhancement ratio (PER) of EFV 
across Caco-2 and Caco-2/HT29-MTX cell monolayers for the free drug and EFV-loaded 
NPs. Results are presented as mean ± SD (n=3). (a) denotes a significant difference (p<0.05) 
when compared with the free EFV. 
 Caco-2  Caco-2/HT29-MTX 
Papp (cm s
-110-6) PER  Papp (cm s-110-6) PER 
EFV 9.3 ± 1.3 –  7.3 ± 1.0 – 
PLGA NPs 4.8 ± 0.6a 0.52  5.4 ± 0.4 0.74 
PEG-PLGA NPs 4.1 ± 0.4a 0.44  5.0 ± 0.7a 0.68 
 
 
4.4.4. Pharmacokinetics of efavirenz-loaded nanoparticles  
 
 The potential of NPs for rectal delivery of EFV was further assessed in vivo 
using a murine model. Drug levels in colonic lavages and tissues, as well as in blood 
plasma, were determined between 15 min and 12 h following administration. The 
colon was divided into three equally sized segments (proximal, middle and distal), as 
detailed in Figure 4.4., in order to better understand the lengthwise distribution of 
EFV. Systemic exposure to EFV was generally low and limited in time following 
administration (Figure 4.4, B). Still, the use of NPs resulted in a mild increase in 
absorption, as inferred from AUC0.25-12h values (Table 4.8), which was significant in 
the case of PEG-PLGA NPs (p=0.0014). Previous PK studies in mice are not 
available for EFV but overall plasmatic concentrations were negligible when 
compared to those obtained for comparable oral doses in other species, namely rats 
and Rhesus monkeys (36). The relatively low dose of EFV administered intrarectally 
(roughly 1% of the amount used for therapeutic purposes if considering the standard 
oral dose of 600 mg for humans and an interspecies allometric scaling factor of 12.3 
(37)), as well as its preferential absorption at the intestinal level (38), justify the 
reduced systemic exposure to the drug.  
Local concentrations are an important predictor of the efficacy of microbicide 
drugs (39, 40). Findings from our previous study concerning the biodistribution of 
NPs following intrarectal administration were considered as the ground basis for the 
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conducted PK work (16). In particular, we showed that 200 nm PEG-PLGA NPs 
were able to reach nearly 40% of the total extent of the colon between 15 min and 2 
h after rectal delivery (16). EFV levels in colonic fluids were estimated by lavage in 
the present work (Figure 4.4, C-D). No significant differences were observed for 
animals treated with either free drug or drug-loaded NPs, except for PEG-modified 
nanocarriers at 15 min in the distal colon. Results for Cmax and AUC0.25-12h denote a 
trend towards higher levels of EFV in fluids when PEG-PLGA NPs were used (Table 
4.8), particularly at the middle colon. Variability among individual animals was high 
and in line with the intense stool trafficking in mice, namely at the distal colon (41), 
that is unavoidable even when considering fasting and cleaning measures 
undertaken during animal preparation. Continuous colonic movement and fecal 
output may also justify the rapid drug clearance observed, within as much as 2 h 
following administration. 
Differences in EFV levels between treatment groups were particularly 
apparent for tissues (Figure 4.4, E-F). Again, variation between intra-group 
individuals limited significance at individual time points, which was only observed for 
PEG-PLGA NPs in the distal colon at 15 min. However, analysis of AUC0.25-12h data 
(Table 4.8) clearly demonstrates that the concentrations of EFV for drug-loaded 
PEG-PLGA NPs were significantly higher than those for the free drug at both the 
distal (p=0.0053) and middle (p=0.0179) segments of the colon. Strikingly, a nearly 
30-fold increase in drug levels was observed in the case of PEG-PLGA NPs in the 
middle colon as compared to free EFV. Significantly higher drug concentrations were 
also noted for PEG-modified NPs as compared to plain PLGA NPs at this colon 
segment (approximately 6-fold increase; p=0.0405). Such results are in agreement 
with our previous observations demonstrating that similar PEG-PLGA NPs can 
enhance retrograde distribution and retention in the colon after intrarectal 
administration (16). Lastly, we were unable to quantify or detect EFV in the proximal 
colon at any given time point or treatment group. Again, these observations appear to 
back up the inability of NPs to distribute past the lower segments of the colon, as well 
as the low systemic absorption and distribution of EFV after rectal administration that 
could provide indirect access to the proximal colon.     
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Figure 4.4. Local and systemic PK profiles of EFV following rectal administration of either 
free drug or EFV-loaded NPs. (A) Schematic representation of the murine large intestine and 
delimitation of the different segments considered for local PK assessment. PK profiles from 
15 min to 12 h are presented for (B) blood plasma, (C, D) distal and middle colon fluids 
(expressed as lavage levels), and (E, F) distal and middle colon tissues. Results are 
presented as mean ± SEM levels of EFV per volume of fluid (plasma or lavage), or per tissue 
weight (n=5). (a) and (b) denote significant differences (p<0.05) when compared with the free 
drug or PLGA NPs, respectively. ND: not detected. 
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Table 4.8. Local and systemic pharmacokinetics of EFV-loaded NPs. Data are presented for fluids and tissues of distal (DC) and middle 
(MC) colon segments, as well as blood plasma, upon rectal administration of free EFV or EFV-loaded NPs. Results are expressed as mean 
± SEM (n=5). (a) and (b) denote a significant difference (p<0.05) when compared with free EFV or PLGA NPs, respectively. 
 Cmax (ng mL-1 or ng g-1)  tmax (h)  AUC0.25-12h (ng h mL-1 or ng h g-1)  Frel 
EFV PLGA NPs PEG-PLGA 
NPs 
 EFV PLGA 
NPs 
PEG-PLGA 
NPs 
 EFV PLGA 
NPs 
PEG-PLGA 
NPs 
 EFV PLGA 
NPs 
PEG-PLGA 
NPs 
DC fluid 16.3 ± 2.2 28.7 ± 13.8 41.9 ± 11.1  0.5 0.5 0.25  18.2 ± 0.7 22.6 ± 4.4  25.0 ± 2.9  – 1.2 1.4 
MC fluid 16.2 ± 6.9 24.9 ± 7.2 79.8 ± 54.6  0.25 0.5 0.5  10.6 ± 0.8 17.5 ± 2.8 38.8 ± 17.1  – 1.7 3.7 
DC tissue 74.2 ±  24.7 798 ± 408 2,969 ± 733  0.25 0.5 0.25  93.0 ± 7.9 605 ± 150 1,258 ± 324a    – 6.5 14 
MC tissue 37.6 ± 14.4 437 ± 165 4,121 ± 2,265  0.5 0.5 0.5  86.9 ± 13.0 412 ± 62 2,558 ± 906a,b  – 4.8 29 
Blood plasma 8.4 ± 1.0 18.5 ± 1.6 22.4 ± 1.3  0.5 0.25 0.25  18.6 ± 3.5 32.6 ± 5.1 43.4 ± 1.7a  – 1.8 2.3 
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Overall, our PK results seem to point out for a clear advantage of using drug-loaded 
polymeric NPs in the context of rectal microbicide development, namely PEG-PLGA 
NPs. The ability of nanocarriers to better distribute and retain in the lower colon may 
be particularly relevant in enhancing local drug levels. Still, there are several 
limitations to the present study that should be considered when analyzing our data. 
First, difficulties in translating to the human scenario are considerable due to the 
striking interspecies differences. Mice present shorter GIT transit time and intense 
peristalsis and stool trafficking (41, 42), which predictably contribute to a shorter 
timeframe for drug/nanocarrier residence at the colorectum. The use of other animal 
models that are phylogenetically closer to humans could reduce these limitations. 
However, our results should be readily translatable into HIV-susceptible humanized 
mice, which are valuable models in early pre-clinical development of microbicides 
including in the determination of dose-response relationships (43, 44). Another 
challenge in our study is the clear distinction between the fractions of EFV that are 
embedded or simply adsorbed at the surface of tissue. Washing procedures of the 
different segments of the colon cannot assure the full removal of natural fluids and, 
thus, tissue levels also account for drug that may be intimately associated with 
deeper layers of mucus and epithelial surface. This potential bias, however, seem to 
be of little concern as parallel issues are also found in human clinical trials when 
collecting biopsies for determining PK/PD correlations of rectal microbicides (45). 
Lastly, the adopted PK study protocol is unable to distinguish between the fractions 
of associated and free drug that contribute to the total EFV levels in biological 
samples from mice treated with drug-loaded NPs. This information could be of 
relevance in understanding the actual amount of EFV available to inhibit viral 
infection, namely at the cytoplasm of HIV-susceptible cells. Our in vitro drug release 
studies results seem to point out to the fast release of EFV under sink conditions, 
which could circumvent any concerns regarding limited availability of free drug in 
vivo. 
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 Asserting the safety of microbicide candidates is crucial 
clinical testing. The local effects of both types of EFV
after 14 days of once daily rectal administration at the same drug dose used in PK 
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perianal area, or fecal content were noted throughout the duration of the study in 
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performed at 
colon of mice treated with free drug or EFV
tissue architecture as compare to either PBS
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In the case of mice treated with N-9 – one of the first microbicide candidates 
meanwhile discarded due to its toxic effects to the rectal mucosa that presumably 
lead to enhanced HIV transmission (46) – the presence of an increased number of 
shed cells at the lumen was apparent although without clear signs of damage to the 
epithelial lining. Such observations were consistent with previous reports showing 
rapid recovery of epithelial integrity following extensive exfoliation caused by N-9 
exposure, both in mice (47) and pig-tailed monkeys (48). Histological analysis of 
middle colon tissues was also performed but no signs of toxicity were found in all 
treatment groups (Figure 4.6).  
 
 
 
Figure 4.6. Representative H&E microphotographs of middle colon sections of mice treated 
with either free drug, EFV-loaded PLGA NPs or EFV-loaded PEG-PLGA NPs. Control groups 
included animals administered with N-9 or PBS, as well as mice undergoing no treatment 
(scale bar=200 µm). 
 
 
 
 Additional assay of IL-1, IL-6, IFN- and TNF- levels was performed in 
selected rectal lavage samples collected throughout the duration of safety studies. 
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Changes in cytokine/chemokine profiles have been shown valuable in assessing the 
onset of pro
increased susceptibility to HIV transmissio
Figure 4.7
baseline and 14 days thus suggesting that neither type of EFV
free drug were able to trigger a pro
were only noted for N
PBS-treated mice. As in the case of histological analysis, rapid luminal clearance and 
epithelial turnover may mitigate larger imbalance in cytokine/chemokine levels. 
Together with increased cell shedding observed during histological analysis, data 
seem to
in screening microbicide safety.
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4.5. Conclusions 
 
 Rectal microbicides hold the potential to play a key role in preventing sexual 
HIV transmission. Nanotechnology-based solutions offer new possibilities for 
developing safer and more effective products but work in the field remains scarce. In 
this work, we proposed a simple nanocarrier comprising FDA/European Medicines 
Agency (EMA)-approved materials for the delivery of the ARV drug EFV. In 
particular, we studied the effect of dense surface modification of EFV-loaded PLGA 
NPs with PEG (by means of poloxamer 407 adsorption) on local PK using a murine 
model. Both types of NPs were able to improve the colorectal availability of EFV after 
rectal administration as compared to the free drug. However, PEG modification of 
EFV-loaded NPs provided prolonged drug residence at higher levels at the lower 
colon, which could potentially translate into enhanced protection from HIV 
transmission. Our results seem to support the usefulness of mucus-diffusive 
nanocarriers in engineering effective and safe rectal microbicides. Nevertheless, 
future work is deemed necessary, namely regarding the correlation between 
enhanced local PK and protection from infection, as well as the design of dosage 
forms that could incorporate and further enhance the performance of PEG-PLGA 
NPs. 
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 5.1. Conclusions 
 
Despite all the tremendous achievements in the field of HIV prevention, much 
work remains to be done. Microbicides, in particular those for rectal use, represent a 
promising strategy for preventing viral transmission. However, the development of 
effective, safe and acceptable products has been slow and characterized by a series 
of breakthroughs and setbacks. Product design and formulation are critical steps in 
the development process of rectal microbicides and nanotechnology-based 
approaches may just be the solution to bypass at least some of the shortcomings 
seen for to more conventional rectal dosage forms. Overall, rectal microbicide 
products should be shown able to effectively protect from HIV infection when used 
consistently, without raising any safety issues. 
In order to comply with the overall aim and specific objectives established at 
the beginning of this work, PLGA NPs were developed using a nanoprecipitation 
method and poloxamer 407 – a triblock copolymer of PEG-PPG-PEG – was 
successfully used to establish a dense non-covalent PEG corona, thus rendering 
mucus diffusive properties to otherwise mucoadhesive PLGA NPs. PLGA NPs and 
PEG-PLGA NPs presented mean hydrodynamic diameter values around 200-220 
nm, narrow size distribution and ZP values varying from slightly negative for PLGA 
NPs to near neutral for PEG-modified ones. In addition to ZP, different analytical 
techniques including 1H NMR, EDS and contact angle measurements were able to be 
used in order to confirm the presence of poloxamer 407 chains at the surface of 
PEG-PLGA NPs, suggesting that dense coverage with PEG was in fact achieved. 
This corona was shown to be relatively resistant to desorption upon up to 24 h of 
washing in vitro. When administered intrarectally to mice, fluorescently-labeled PLGA 
NPs and PEG-PLGA NPs featured distinguishable behavior, as assessed by 
qualitative and quantitative techniques. Although both types of NPs were able to 
rapidly migrate and distribute throughout the last two thirds of the colon, only small 
fractions of the total administered NPs (up to around 15%) were able to be recovered 
from the colorectal lumen and tissues after 15 min post-administration. Retention of 
PEG-PLGA NPs was, however, consistently higher up to at least 2 h as compared to 
PLGA NPs (approximately 5- to 10-fold). Also, fluorescent microscopy imaging of 
transverse sections of the colon showed that PEG-PLGA NPs were able to better 
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spread over the epithelial surface and reach the deep folding of the large intestine, 
whereas distribution of PLGA NPs was mostly confined to the gut lumen. Moreover, 
PEG-PLGA NPs were demonstrated as being able to actually penetrate colorectal 
tissue. 
The previous results encouraged moving forward with the comparison 
between PLGA NPs and PEG-PLGA NPs, namely concerning their potential as 
carriers for the model microbicide drug EFV. Both type of drug-loaded NPs were 
produced by easily adapting the developed nanoprecipitation method and were 
shown to maintain similar characteristics to non-loaded counterparts. High and 
comparable AE (>80%) and DL (around 4%) values were obtained for both PLGA 
NPs and PEO-PLGA NPs, which featured rapid drug release under sink condition. 
Drug association to NPs did not substantially affect the ARV activity of EFV against 
HIV-1 as assessed in vitro. However, an improvement to the intrinsic toxicity profile of 
the drug was noted, which led to larger SI values for drug-loaded NPs. Both types of 
NPs were also found to present low toxicity to different colorectal epithelial cells lines, 
thus showing to be potentially safe. Furthermore, NPs were able to be readily taken 
up by Caco-2 and HT29-MTX cells, while permeability studies using cell monolayer 
models showed a mild decrease in the transmembrane transport of EFV when 
associated to NPs. These results appear to emphasize the ability of NPs to interact 
with colorectal cells, which could be seen as beneficial in order to enable the drug to 
reach deeper mucosal levels and to be delivered to the vicinities of (or even directly 
to) HIV target cells, while potentially limiting systemic exposure. 
The results described above considered as positive and justified the in vivo 
assessment of the PK and safety profiles of both types of EFV-loaded NPs. After 
rectal administration to mice, both types of nanosystems allowed reaching higher 
drug levels in colorectal tissues and fluids as compared to the free drug. Still, rapid 
depletion of EFV was observed, likely related to the typically fast leakage of materials 
observed in mice following rectal administration. Nonetheless and in line with data for 
in vivo distribution and retention of NPs, EFV appeared to have distributed 
retrogradely and reached several centimeters upwards into the colon. Generally, 
PEG-PLGA NPs displayed higher local drug levels as compared to PLGA NPs, 
although differences were only significant when considering colorectal tissues. Again, 
these results seemed to be in accordance with the distribution and retention patterns 
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observed for PEG-modified and non-modified PLGA NPs, and seem to support 
mucus diffusive NPs as better suited carriers for enhancing the PK of EFV at the 
colorectum. Systemic exposure to EFV was generally low when either free drug or 
drug-loaded NPs were used. Finally, both types of NPs were found safe after daily 
rectal administration for 14 days, thus indicating that particularly EFV-loaded PEG-
PLGA NPs may be useful for developing a rectal microbicide product. 
Overall, data presented in this work support that polymeric NPs may constitute 
interesting drug carriers for developing rectal anti-HIV microbicides. Adequate 
engineering of the surface properties of PLGA NPs, namely by granting mucus 
diffusive properties through means of dense, non-covalent coating with PEG, 
provides a simple yet powerful way to enhance microbicide drug levels at the 
colorectum. This, in turn, may allow conferring higher degree of protection against 
sexual transmission of HIV upon RAI. 
 
 
5.2. Future perspectives 
 
“Science never solves a problem without creating ten more.”  
George Bernard Shaw 
 
Scientific research is a never ending story, typically raising other issues that 
require further assessment. The present work is no exception, presenting limitations 
and several aspects that may be improved and/or implemented in future studies. 
Some of the limitations of the present work were already discussed throughout the 
document and will not be again addressed in this section. However, some reflections 
on subsequent work and new directions seem appropriate. 
Firstly, some aspects concerning the formulation of NPs could be re-visited. 
For example, other ARV drugs could be tested in order to confirm the broad potential 
of the proposed systems to deliver different molecules of interest. This would also 
allow developing combination microbicides based on nanocarriers featuring two or 
more ARV drugs, preferentially with different targets in HIV infection cascade. Co-
association to NPs could be tested but individual incorporation of ARV drugs of 
interest during the production process would likely be an easier in order to fine tune 
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the properties of obtained nanosystems. The rapid in vitro release of EFV (and 
possibly of other candidate drugs) observed under forced sink conditions may be an 
issue requiring revision. Although PK results indicate that such behavior may not 
have occurred under physiological conditions, improvements could be pursued, 
namely by changing the composition of NPs (e.g., use of other types of PLGA, 
inclusion of complexing agents, etc.). Concerning the possibility for further 
functionalization, proposed NPs could benefit of the surface immobilization of specific 
targeting agents that could benefit the specific delivery of EFV to HIV-susceptible 
cells. The development of targeted nanosystems may help improving the efficacy and 
safety of microbicide products. Obvious targeting moieties include, among others, 
agents that are able to bind host cell surface receptors involved in HIV transmission 
and infection (e.g., CD4, CCR5, DC-SIGN) (1). Another aspect that was not explored 
in this work concerns the development of actual products that could be able to be 
directly translated into clinical tested. NPs were used as a PBS suspension, which 
may be generally considered as representative of enemas. However, the influence of 
including additional excipients of interest (e.g., preservatives, humectants, stabilizers, 
etc.) or even considering other dosage forms (e.g., gels, soft capsules) on the 
performance of both types of NPs deserves further investigation. Other relevant 
issues pertaining to formulation development and clinical translation that should be 
further addressed even at this early stage of the development process include 
scaling-up, manufacturing, quality control and stability of drug-loaded NPs. 
In addition to the already generated in vivo distribution and retention data, 
knowledge on the behavior of both PEG-modified and non-modified PLGA-based 
NPs in animal models that could proxy the reality of RAI would be helpful. For 
example, it may be expected that the presence of semen (or semen simulant) or the 
occurrence of simulated penile penetration can impact to some extent the distribution 
and retention of NPs in the colorectal compartment. 
The in vitro ARV studies conducted were limited particularly regarding the type 
of infection model and number of HIV strains used. While TZM-bl cell-models are 
useful for early activity screening of ARV compounds, they lack the ability to mimic 
important features of in vivo scenarios typical of RAI such as the presence of 
mucosal fluids and semen, shear caused by penile penetration or resting bowel 
movement. Also, the absence of a complex mucosal tissue composition and 
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architecture limit the usefulness of TZM-bl cell-models. For example it would be 
interesting to use human colorectal explants in order to assess the ability of drug-
loaded NPs to abbreviate infection by HIV. The inclusion of semen and/or native 
mucus, simulation of the natural depletion of compounds/carriers or testing of 
multiple viral exposures in such models is also possible and could provide interesting 
hints as to the potential of proposed NPs (2, 3). For instance, the role of semen in 
HIV infection by the rectal route is an important topic that remains poorly understood. 
While some data suggests the impairment of HIV infection by semen, another points 
that semen components may facilitate the HIV transmission (4). Moreover, some 
studies suggest that the influence of semen in HIV infections may depend on the 
antiviral agent used (5). So, it is important to understand the differences in the 
antiviral activity of EFV-loaded NPs in the presence of semen, since it may lead to 
variable results (6). Also, expanding the panel of HIV-1 strains used for testing ARV 
activity, namely by including resistant or MSM-derived transmitted/founder (T/F) 
viruses, would be interesting (7, 8). 
Despite being useful, colorectal explants lack the definitive in vivo environment 
and the effect of some factors are not able to be studied in this kind of ex vivo 
models. Therefore, testing EFV-loaded NPs in animal models of infection would be of 
paramount interest. For, example, humanized murine models of HIV infection have 
been used to evaluate the effectiveness of vaginal and rectal microbicides (7, 9). 
Importantly, the relevance of PK data generated in the present study could provide 
an important starting point for planning experiments in humanized mice. Other 
relevant animal models for testing rectal microbicides include NHPs (10, 11). Despite 
important limitations, these are considered the most relevant species before 
translation into humans and, if possible, drug-loaded NPs should be tested in such 
models. Overall, the use of an in vivo efficacy model would provide a more realistic 
environment in order to understand the real impact of developed drug-loaded PLGA 
NPs in the prevention of HIV transmission (7). 
Although generated data points out to the potential safety of developed 
nanosystems, such studies should be expanded in order to further support translation 
into clinical testing. For example, it would be interesting to study the toxicity of 
nanosystems in human colorectal explants, similar to those used for testing efficacy 
(12). Also, detailed and prolonged in vivo testing of the drug-loaded NPs, namely in 
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different animal models (e.g., rats, rabbits) would be advisable. The local microbiota 
is essential to maintain the homeostasis in a symbiotic relationship with the host (13, 
14). Any factor affecting microbiota may cause of profound alterations in this 
relationship (15). Furthermore, microbiota can have impact on the metabolism of 
various drugs and this possibility should be considered for EFV and EFV-loaded 
NPs. So, the evaluation of the interactions of NPs with rectal microbiota would be a 
relevant upgrade to the already conducted work. 
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